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ABSTRACT 
Cystatins are the endogenous thiol proteinase inhibitors found ubiquitously in the 
physiological system. Inhibitors showing evolutionary, structurally and functionally 
significant correlation to cystatins have been grouped into cystatin superfamily. 
Cystatin superfamily has been divided into three families stefm, cystatin and 
kininogen on the basis of the number of amino acids, disulphide bonds and 
carbohydrate content. Regulation of the activities of CP by their inhibitors is 
important to maintain a balance between the proteinase and antiproteinase. 
Cystatins are competitive, non-covalent and tight binding inhibitors. They have 
reportedly been purified fi^om a number of mammalian sources like muscle, spleen, 
heart and liver. However, lacuna existed in the isolation and purification of 
cystatin from most important mammalian organ that is kidney. 
In the present study purification of cystatin from goat kidney has been achieved 
by simple three step procedure which includes ammonium sulphate fi^actionation, 
gel filtration on Sephadex G-75 and ion-exchange chromatography on DEAE-
cellulose. The preparation was found to be homogenous on the basis of molecular 
weight however when the pooled fractions from gel chromatography were 
subjected to DEAE-cellulose column two homogenous inhibitor isoforms were 
obtained with a yield of about 60.8% and 40% and fold purification of 266.5 
and 229, respectively. The isoforms I and II have Mr of 67KDa consisting of 
single polypeptide chain as found by gel filtration and SDS PAGE. The stokes 
o 
radius of the isoforms was also identical, 35.3A. They are devoid of disulphide 
bonds and contain carbohydrate content as 1.8% and 2.9% for isoforms I and II, 
respectively. Both the inhibitors exhibited remarkable stability in the temperature 
range of 35'C - 95"C and wide range of pH (3-10) and showed antibacterial 
activity against Staphylococcus aureus. Bacillus sub til is. Streptococcus hemolyticus. 
Escherichia coli and Pseudomunas fluorescens. 
(vi) 
The 15 residue N-terminal sequence analysis showed low homology to chicken 
cystatin and human cystatin S and no homology to cystatin A, B, D, E and F. 
Comparatively higher sequence homology to type III cystatins (33.3%) was 
observed. The conserved glycine (which is present at position 9 in many cystatins) 
was found at position 15 in the purified cystatins. Analogous cleavage pattern by 
nonspecific proteases was observed. Chymotrypsin cleaved the cystatin into two 
domains although trypsin did not cleave the inhibitors. The antiserum against the 
isoform II showed cross reactivity among the two isoforms and complete identity 
with LMW kininogen. 
The purified cystatin exhibited major fluorescence spectral changes in the presence 
of papjun. The CD studies revealed precisely the secondary structural composition 
of isoforms I and II. Isoform I was composed of 29.6% a-helix, 9% P-structure, 
27.9 P-turn and 33.5% random structure. Similarly, a predominant helical structure 
was obtained in isoform II with 25.5%. a-helix„ 17% p-structure, 22.4% P-tum 
and 35.2%) random structure. 
The inhibition kinetics studies revealed that the cystatin isoforms are competitive 
tight binding inhibitors. The major finding being the inhibition of bromelain by 
these isoforms, although the aflTinity was low. The Ki values obtained were 
2.1xlO'^'M and SxlO'^M with papain, 9xlO-'°M and SxlO'^M with ficin and 
2.2xlO"'M and 1.7x10' with bromelain for isoforms I and II, respectively. Papain 
exhibited highest affinity compared to ficin and bromelain. Highest association rate 
of l.SxlO'^M's"' and 8.6xlO''M~'s'' was obtained for papain for isoform I and II 
respectively. Dissociation rate constants of 6.14xl0'*s"' and 5.75x10^^5' with papain, 
5.37xlO-*s' and 4.6xl0-^s-' with bromelain and 1.63xl0-'s-' and 2.3x10-^8' with 
ficin for isoform I and II was obtained, respectively. 
( v i i ) 
Cystatin underwent damage and degradation by the ROS produced by riboflavin 
mainly due to singlet oxygen and hydroxyl radical. The damage was further 
examined by fluorescence spectra. The results showed rapid and major 
spectroscopic changes in the cystatin conformation on exposure to ROS. 
The novel properties of cystatin like high molecular weight, absence of di sulphide 
bonds, presence of carbohydrate moieties, antibacterial activity, high stability to 
wide temperature and pH range, unique N-terminal 15 amino acid residue 
sequence, different cleavage pattern by chymotrypsin and trypsin, composition of 
secondary structures, the kinetics of inhibition which describe these isoforms to be 
competitive and tight binding inhibitors and susceptibility to ROS suggest that it 
cannot be placed in any of the known families of cystatin . The characteristics 
are intermediate between type I, II and III cystatins. Hence, the name cystatin K 
is proposed to place it in a new class of cystatins. 
( v i i i ) 
Dntroduction 
1. INTRODUCTION 
GENERAL 
Thiol proteinases synonymous with cysteine proteinases are widely distributed 
among living organisms (Barrett et al., 1986). They are proteins of Mr of about 
25-35KDa. These proteinases are synthesized in a precursor form in order to 
prevent unwanted proteolysis. They are subjected to co-translational and post 
translational modifications that convert them to catalytically active mature en2ymes 
(Turk et al., 1996; Cygler et al., 1996; Turk et al., 2000). Thiol proteinases play 
an important role in the intracellular proteolysis such as catabolism of proteins 
and peptides, processing of prohormones and precursor proteins and in MHC 
class II- restricted antigen processing and presentation (Turk 2000; Turk et al., 
1997; Turk, 2001; Stoka, 2001). These proteins contain two principal catalytic 
amino acid residues, cysteine and histidine which are involved in the cleavage of 
peptide bonds connecting the amino acid residues of a protein or peptide 
substrate (Storer 1994; Stennicke, 1999). 
Four types of proteinases are there: acid proteases require low pH values for 
their activity. They cleave non polar amino acid residues on either side. Serine 
proteases require a serine residue at their active site. Cysteine proteases have 
cysteine residue at their active site. Metalloenzymes require the presence of metal 
ions for full activity. 
Mammalian thiol proteinases have been classified into four different types: 
1. Cathepsins 2. Legumain 3. Calpains 4. Caspases 
Cathepsins and legumain are found in the lysosomes of the cells. Cathepsins are 
relatively small proteins with the exception of cathepsin C which is an oligomeric 
enzyme of Mr of about 200KDa. They are involved in intracellular protein 
turnover, proteolytic degradation and cleavage of a number of precursor proteins 
and hormones their concentration is particularly high in spleen (Otto, 1971; 
McDonald and Elis, 1975; Bajkowski, 1975), kidney, liver (Knight, 1980; Quinn 
and Judah 1978), lung (Singh and Kalnitsky, 1978), brain (Suhar and Marks, 
1979), and breast (Mort et al.,1980). 
Legumain is an asparaginyl endopeptidase that was found to be involved in MHC 
class n - restricted antigen presentation (Manoury et al., 1998) and local negative 
regulation of osteoclasts formation and activity (Choi et al., 1994). 
However, calpains and caspases are cystoplasmic thiol proteinases. Yajima and 
Kawashima (2001) proposed that mammalian calpains have higher Mr of about 
llOKDa and participate in many intracellular processes such as turnover of 
cystoskeletal proteins, cell differentiation and regulation of signal polypeptides. 
The central component of cell apoptosis, consists of proteolytic systems involving 
caspases (Nicholson, 1999; Stennicke et al., 2000). Caspases are the cysteine 
dependent aspaifete specific proteinases. 
About 40 different families of cysteine proteinases have so far been characterized 
(Barrett et al., 1998). The first clearly recognized and extensively studied cysteine 
proteinase was papain, isolated from the latex of the plant, Carica papaya. Neariy 
half of the known families of cysteine peptidases are represented only in viruses, 
some occur in bacteria, whereas others exist in eukaryotic organisms (Rawlings 
and Barrett, 1994). Current evidence suggests that all eleven lysosomal cathepsins 
known to date (B, H, L, S, C, K, O, F, V, X and W) are members of papain 
family (Kotyza and Krepela, 2002) 
Regulation of Lysosomal Thiol Proteinase Activity 
Starvation of animals increases the rate of protein degradation in liver (Dice et 
al., 1978) and muscle (Li and Goldberg, 1976) and causes about two fold 
increase of cathepsin D and A level in the liver (Katunuma et al., 1982). 
Similarly, several hormones are knov^n to regulate average rates of protein 
degradation. Various pathological conditions have been associated with increased 
thiol proteinase activities like metastasizing cancer (Koppel et al, 1994), muscular 
dystrophy (Noda et al., 1981), renal failure (Kabanda et al., 1995), rheumatoid 
arthritis (Gabrijeleic et al., 1990) etc. Hence, the wide implication of the thiol 
proteinases in various biological functions need to be effectively regulated by 
opposing effect of the activators and inhibitors. Natural inhibitors of cysteine 
proteinases included the members of cystatin superfamily: stefins, cystatins and 
kininogens. These cystatins constitute a powerful regulatory system for endogenous 
cysteine proteinases which may otherwise cause uncontrolled proteolysis and tissue 
damage. 
Discovery of Cystatin Superfamily 
Protein inhibitors of cysteine proteinases in mammalian tissues were first reported by 
Finkelstadt (1957), who reported a heat stable inhibitor of cathepsin B and dipeptidyl 
peptidase I in rat liver cytosol. Whitaker and coworkers discovered and partially 
characterized a protein from chicken egg white that inhibits ficin and papain 
(Fossum and Whitaker, 1968; Sen and Whitaker, 1973). This protein also inhibits 
cathepsin B and dipeptidyl peptidase I as reported by Keilova and Tomasek 
(1974; 1975). 
The term cystatin was originally given by Barrett (1981) for the protein because 
of its unique propeny of arresting the activity of CPs. Later, the name was given 
to a superfamily of evolutionary, structurally and functionally related proteins 
involved in the inhibition of CP activities. 
Later on, CPI from various mammalian tissues were isolated and characterized. 
These inhibitors resembled chicken cystatin in relative molecular mass and 
physiochemical properties. Subsequently, Machleidt et al (1983) reported that the 
sequences of stefin also called 'cystatin A' and chicken cystatin are homologous 
(Green et al., 1984; Barrett, 1985). Stefin however, differed in lacking cysteine 
residues and hence, was placed in a different family within cystatin superfamily. 
All cystatins fall into a single superfamily i.e. a group within which all the 
members can be shown to have a statistically significant relation but they do not 
resemble members of other superfamilies (Dayhoff et al., 1979a). Cystatin 
superfamily contains atleast three distinct families, the members of which are 
expected to have atleast half of their amino acid residues in common (Dayhoff et 
al., 1979b). 
CLASSIFICATION OF CYSTATIN SUPERFAMILY 
The first international symposium on Cysteine Proteinases and their Inhibitors in 
1985 decided that these inhibitors should be divided into three families 1, 2 and 
3 (Barrett et al., 1986). Hence, the proteins of cystatin superfamily are divided 
on the basis of sequence homology, molecular structure and the number of amino 
acids (Rawlings & Barrett, 1990; Turk et al., 1997; Brzin et al., 1984; Turk and 
Bode, 1991) Figure 1.1. 
Family 1 (Type I Cystatin): Stefins 
The name stefin has been assigned to this family to emphasize the structural 
difference between these proteins and cystatins. The proteins of this family are the 
1.1 Diagrammatic representation of the chain structure of proteins in 
the cystatin superfamily 
The structure indicated for kininogens is that of L-kininogens; 
H-kininogens have a longer carboxyl terminal extension. The symbol 
i marks potential sites for the attachment of the carbohydrate side 
chains. 
Type I 
- - — • - - - - , _ - - , n _ _ I I I - - I — - | ^-•r^-^ 
Type 11 
I • • » < — * — » — — — » • — — < • _ft_D 
Type III 
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smallest among the members of the cystatin superfamily lacking disulphide bonds 
and carbohydrate moieties. Stefins are single chain proteins, synthesized without 
signal peptides and consist of about 100 amino acid residues (Mr 11000). All 
type I cystatins have blocked N-terminal and contain methionine representing the 
points of initiation of translation. They occur both intracellularly and 
extracellularly. There are three important members of this family cystatin A and B 
isolated from human and stefin C from bovine tissues. Cystatins a and P are 
considered to be simply the rat species variants of cystatins A and B. The amino 
acid sequence of these proteins closely resemble each other. 
Cystatin A 
It is an inhibitor of cathepsin B in human skin discovered by Fraki (1976). Later 
on Jarvinen (1978) studied it as ACPI 'acid cysteine proteinase inhibitor'. Brzin et 
al (1983) purified an inhibitor from blood leucocytes and named it 'stefin'. The 
amino acid sequence was determined by Machleidt et a! (1983). Green et al 
(1984) characterized same type of CPI from human liver and later renamed it as 
cystatin A. 
Cystatin A occurs in multiple isoelectric forms with predominantly acidic pi values 
in the range 4.5-5.0 (Jarvinen, 1978; Hopsu-Havu et al., 1983a). . 
Rinnie et al (1978) detected cystatin A in extracts of squamous epithelia from 
oesophagus. It was also found in dendritic reticulum cells of the lymph nodes 
(Rinnie et al., 1983), seminal plasma (Minakata and Asano, 1985), saliva, bovine 
skin (Turk et al., 1995), human nails (Tsushima, 1993) and in a number of 
epidermoid carcinomas (Rinnie, 1979; 1980; Rinnie et al., 1980, 1984a). 
Physiological concentration of human cystatin A was reported by Hopsu-Havu et 
a) (1983b) in serum i\0-\5iiQjm\). In tissues the concentrations were: epidermis of 
tongue and mouth, 65-200ng/g; bone marrow, 8|ag/g; liver, 5ng/g; spleen, 3ng/g 
and lung, 0.3 ng/g. 
Cystatin a is assumed to be a species variant of cystatin A found in rats. 
This protein was characterized by Jarvinen (1976) as specific inhibitor of CP irom 
rat skin having Mr of 13000. Cystatin a is generally found on the epidermal 
layer (Jarvinen et al., 1978) and various other squamous epithelia (Rinnie et al., 
1978).Kominami et al (1984a) and Katunuma and Kominami (1985) quantified the 
concentration in skin and small intestine as 2800|ig/mg protein and 820jig/g 
protein, respectively. The serum level of cystatin a in rat was 2.5ng/ml. 
The N-terminal sequence of bovine stefin A was identified as a truncated form of 
bovine cystatin C (Hirado et al., 1985; Turk et al., 1995). The sequence identity 
is 86% and 88% with human cystatin A N- and C- terminal part. 
Cystatin B 
Cystatin B was detected as an inhibitor of cathepsin B and H in human tissues 
by Lenney et al (1979). Jarvinen and Rinnie (1982) purified cystatin B from 
human spleen. Green et al (1984) purified cystatin B from human spleen and liver 
with separation of multiple forms. Cystatin B is a relatively basic protein with pi 
values of 6.25 and 6.35 for the two forms of cystatin B (Green et al., 1984). 
Jarvinen and Rinnie (1982) reported pi values of 6.0 and 6.5 and Rinnie et al 
(1984b) reported 6.5 and 7.5. Human cystatin B forms dimers (Jarvinen and 
Rinnie 1982; Green et al., 1984; Rinnie et al., 1984b). Dimeric form is not 
inhibitory active. 
Cystatin B is ubiquitously distributed in various cells and tissues like epithelial 
cells, lymphocytes (Davies and Barrett, 1984), monocytes (Hopsu-Havu et al 
1984; 1985b) and to much lesser extent in seminal plasma (Brzin, 1982). Jarvinen 
et al (1983) have shown cystatin B in cells of the upper layers of epithelium of 
the oral mucosa. Confocal microscopy analysis showed the localization of cystatin 
mmnly in the nucleus of proliferating cells and both in the nucleus and cytoplasm 
of differentiated cells (Riccio, 2001). This cystatin is involved in the protection 
against uncontrolled activity of host lysosomal CP (Henskens, 1996). Crystal 
structure of recombinant human cystatin B has been elucidated by X-ray 
crystallography analysis (Stubbs et al., 1990). Cystatin B is more abundant in all 
cells than cystatin A with the exception of PMNs. 
Finkelstadt (1957) and Lenney (1979) reported the existence of thermostable and 
dialysable inhibitor of cathepsin B, H and dipeptidyl peptidase I in the supernatant 
of rat liver homogenate. Subsequently, Hirado et al (1981) isolated cystatin P 
from rat liver cytosol. The pi values for cystatin P range from 5.04 (Hirado et 
al., 1981) to 5.6 (Kominami et al., 1981).Cystatin P has an almost even 
distribution in the tissues and is more abundant than cystatin a in all tissues 
except skin. This characteristic of cystatin P resembles cystatin B of human 
variant. Stefm B from bovine was reported by Krizaj et al (1992). 
Stefin C 
Several low Mr CPI have been found in bovine thymus. Although kinetically 
similar they differ in the primary structure and pi values. Stefin C is unique 
among the inhibitors from stefm family which was found in multiple forms 
resulting from the cleavage of Asn 5-Leu 6 bond of the inhibitor (Turk et al., 
1993). This property is common to stefms and low Mr CPI (Barret et al., 1986; 
Brzin et al., 1982; Kopitar et al., 1989).The protein consists of 101 amino acid 
residues and its Mr is calculated to be 11,546. The inhibitor was found to be 
acidic with pi values from 4.5 and 5.6 (Turk et al., 1993). 
Stefin C exhibits considerable sequence homology with other inhibitors from stefin 
family with maximum homology of 84.7% with bovine stefin B, 72.4% with 
human cystatin B and 47.9% with human stefin A. It was identified as the first 
tryptophan (at position 2) containing stefin and it had prolonged N-terminal (Turk 
et al., 1993). 
Family 2 (Type II): Cystadns 
Family 1 and 2 CPI are low Mr cystatins. These inhibitors are composed of 115-
120 amino acid residues having Mr of about 13000. Cystatins contain two 
disulphide bonds and lack carbohydrate. They are synthesized with the signal 
peptide and found at a relatively high concentration in secretions like chicken egg 
white, seminal plasma, saliva, etc. They originate in cells and may also fiinction 
intracellularly. The known members of this family are chicken cystatin, human 
cystatin C, D, S, SN, SA, E, F and M. Measurements of the concentration of 
cystatin in human biological fluids reveal that all such fluids contain inhibitors, but 
the total molar ratios of diflferent inhibitors vary markedly, cystatins are found 
both in cells and tissues(Lofberg et al .,1983) The general pattern seems that 
secretions contain the highest concentration of family 2 cystatins (Abrahamson, 
1994). 
Family 2 cystatin genes are clustered in a multigene locus on chromosome 20 
together with two pseudogenes (Abrahamson et al., 1990; Schnittger et al., 1993; 
Thiesse et al., 1994). The best known representatives of this class of cystatins are 
human cystatin C and chicken cystatin.The pi values range from 4.4 to 9.3. 
Cystatin C 
Originally cystatin C was termed as y-trace or post y-globulin from human CSF 
because of its basic nature and y-electrophoretic mobility (Clausen, 1961; 
MacPherson and Cosgrove, 1961; Barret et al, 1984a; Brzin,1984). It was also 
found in urine from patients with renal failure (Butler and Flynn, 1961) and 
ascitic and pleural fluids (Hochwald and Thombecke, 1962). Later, cystatin C was 
also detected in saliva and normal serum (Cejka and Fleischmann, 1973) and in 
seminal plasma (Colle et al., 1976).Lofl)erg and Gnibb (1979) determined cystatin 
C concentration of 5.8(xg/ml in CSF, 1.8mg/ml in saliva, 0.095 |ig/ml in normal 
urine, 21|ig/ml in urine from patients with renal tubular disorders and l.lng/ml in 
normal plasma. Seminal plasma contains SOpig/ml i.e. 36 fold higher concentration 
of inhibitor than in normal blood plasma (Grubb et al., 1983). Abrahamson found 
cystatin C concentration of 3.4|ag/ml in saliva from submandibular glands and 
0.9|ig/ml from the parotid gland.The high level of cystatin C in the CSF 
compared with blood plasma suggests the production of cystatin in the central 
nervous system (Loflierg and Grubb, 1979). The protein is able to cross blood 
brain barrier to the vascular space thereby rapidly fiUered in the glomeruli and 
catabolised in the renal tubular cells. 
Despite widespread extracellular distribution, cystatin C has also been detected 
intracellularly in brain cortical nerves (Lofberg et al., 1981a), normal and 
neoplastic neuroendocrine cells in the adrenal medulla (Lofberg et al., 1982),A 
cells of pancreatic islets (Lofberg et al., 1981b), thyroid (Lofljerg et al., 1983) 
and pituitary (Lofl^ erg et al., 1984; Moller et al., 1985). Homologues of human 
cystatin C have been found in several mammals including mouse, rat, cow, and 
dog (Solan et al., 1990; Esnard et al., 1988; Hirado et al., 1985; Poulik et al., 
1981) 
Cejka and Fleischmann (1973) determined the isoelectric point of cystatin C to be 
9.0 ahhough, values ranging from 8.0 (Brzin et al., 1984) to 9.5 (Laurenzi and 
Link, 1978) have been reported. Degradation of N-terminal takes place during 
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storage, which results in a lower pi value (Tonelle et al., 1979). N-terminal 
truncation of cystatin by cathepsin L has been reported by Popovic et al (1999) 
which leads to total loss in its activity and lowering of pi to 8.1 and 8.25 due 
to loss of one or more basic residues. It was suggested that cleavage could be 
of physiological significance to control the extent of inhibition of cathepsin B at 
the site of inflammation (Abrahamson et al., 1991). The truncation results in the 
exposure of N-terminal and loss of ordered structure of cystatin in solution (Ekiel 
et al., 1997). 
Chicken cystatin was first isolated from chicken egg white by Fossum and 
Whitaker (1968) and Sen and Whitaker (1973) as low Mr tight binding CPI of 
ficin and papain and of cathepsin B and C (Keilova and Tomasek, 1974; 1975). 
Chicken cystatin has also been detected in the serum of both male and female 
chicken (Anastasi et al., 1983) and in chicken muscle cell (Wood et al., 1985) 
and it resembles cystatin C. 
Chicken cystatin is present at a concentration of 80|xg/ml in egg white and at 
about li^g/ml in the serum (Anastasi et al., 1983). A Mr of about 13,000 has 
been determined from the amino acid composition (Lindahl et al., 1988). Nicklin 
and Barrett (1984) resolved the two isoelectric forms I and II having pi values 
of 6,5 and 5.6, respectively. Chicken cystatin has been crystallized and preliminary 
X-ray crystallography data showed crystals of trigonal space group P3, 21 with 
all constants a=b=47.9A, C=87.5A, a=p=90^ Y=120'^, which contain one molecule 
per asymmetric unit (Bode et al., 1985). 
Cystatin I) 
Freije et al(1991) cloned a new member of human cystatin multigene family from 
a genomic library using cystatin C cDNA probe. This inhibitor consists of 122 
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amino acid residues having a Mr of 13,885. The deduced amino acid sequence 
includes a putative signal peptide and has 51-55% homology with either cystatin 
C or secretory gland cystatins S, SA and SN. 
Cystatin D is a relatively neutral protein with pi values in the range 6.8 to 7.0 
(Freije et al., 1991). Cystatin D is expressed in parotid gland, saliva and tears 
(Balbin et al., 1994).This tissue restricted expression is in marked contrast with a 
wider distribution of all other family 2 cystatins. 
Cystatin S 
Human saliva contains several low Mr acidic proteins which include CPI also 
(Isemura et al., 1984b; Minakata and Asano, 1984). The first salivary inhibitor 
purified and sequenced was SAP-I (Isemura et al., 1984a), which was renamed 
'cystatin S'. It was found to have 54 and 41% sequence homology with cystatin 
C and chicken cystatin, respectively (Isemura, 1984 a,b). Cystatin S contains no 
phosphate, in contrast to other salivary proteins (Isemura et al., 1984b). This 
inhibitor has also been isolated from human submaxillary, submandibular and 
sublingual gland and found to be present in the serous cells of parotid and 
submaxillary glands (Isemura, 1984b). It is assumed that these cells are 
responsible for its synthesis. The protein has also been found in tears, serum, 
urine, bile, pancreas and bronchus (Isemura et al., 1986). 
Shaw et al (1988) indicated that the protein in IPR treated rats is a cystatin 
belonging to family 2 of the cystatin superfamily and named it rat cystatin S. Rat 
SN cystatin has also been purified from the submandibular glands of rats 
subjected to chronic IPR treatment (Bedi, 1989a) and its amino acid sequence has 
been determined by Bedi (1989b). 
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Variants of Cystatin S 
Several molecular variants of cystatin S have been studied by Isemura et al 
(1986). They differ in their N-terminal sequences and pi values (Minakata and 
Asano, 1984; Isemura, 1986; Shomers et al., 1982ab). Diflferences in pi values 
result from phosphorylation of residues Ser 3 or Ser 1 in salivary cystatin 
(Isemura et al., 1991). 
Cystatin SN: Originally known as cystatin SV or SA-1 (Abrahamson et al., 
1986). The protein consists of 121 amino acid residues and Mr value of 14,316. 
The pi value is in the range of 6.6-6.8. 
Cystatin SA: The protein consists of 121 amino acid residues and Mr value is 
slightly higher than cystatin SN, which is 14,351. It has acidic pi value of 4.6 
(Isemura et al., 1991). Cystatin SA isolated from saliva had N-terminal residue 
Glu(Isemura et al., 1986). 
Cystatin E 
Ni et al (1997) found this type of cystatin by expression of the amniotic cell and 
fetal skin epithelial cell cDNA libraries. The mature protein is a polypeptide of 
121 amino acid residues and has 28 residue signal peptide having a Mr of 
15,000. Cystatin E resembles family 2 cystatins structurally in containing two 
protective disulphide bridges and by being a secreted protein. The inhibitor has 
unusual characteristic of being a glycoprotein carrying an N-linked oligosaccharide 
at Asn 108. 
Cystatin E is a functional tight binding CPI despite relatively low amino acid 
sequence similarities with human family 2 cystatins (C, D, S, SN and SA) of 26-
34% and 18 and 23% with family 1 cystatin A and B and less than 30% with 
domains 2 and 3 of the family 3 cystatins, kininogens (Ni et al., 1997). The 
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protein has Pro-Trp pair towards the C-terminal Hke that of family 2 and 3 
cystatins. Cystatin E gene has been localized on chromosome 11 (Stenmann et al., 
1997) 
Cystatin E has been detected in a variety of specialized tissues and organs (Ni et 
al., 1997). High concentration has been found in uterus and liver, lower but 
significant amounts in placenta, pancreas, heart, spleen, small intestine and 
peripleural blood leucocytes and low cystatin E content in brain, testis and kidney. 
The inhibitor serves a protective role during fetal development. 
Cystatin F 
Another described human member of the cystatin superfamily was identified as 
cystatin F by Ni et al (1998). The whole sequence contained signal peptide and 
a mature protein of 126 amino acid residues with two disulphide bonds which 
resembles family 2 cystatins. Unlike other members, cystatin F has two additional 
Cys residues indicating the presence of an extra disulphide bridge which stabilizes 
the N-terminal region of the molecule. The mature protein has an extended N-
terminal segment, being 6-10 residues longer than the other single domain 
cystatins. Cystatin F has a Mr of 14,543 as determined by sequence analysis (Ni 
et al., 1998). 
Cystatin F has two N-linked carbohydrate chains at positions 36 and 88. It has 
30-34% homologous sequence to human family 2 cystatins, only 29% homology 
to cystatin E, even lower 22-20% identities to cystatin A and B, 24% with 
domain 3 of kininogens. 
The distribution pattern of cystatin F is very different from that of cystatin C or 
E, Blood contains low levels of the inhibitor (0.9ng/ml). The highest 
concentration is present in the spleen and peripheral blood leucocytes, moderate 
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levels in thymus and small intestine. Cystatin F is found mostly in the immune 
cells. However, it could not be detected in B cell lines but appreciable amounts 
were detected from primary dendritic cells, anergic T-cells, bone marrow, activated 
T-cells, multiple sclerosis lesions, osteoarthritic, breast, lymph node, apoptotic T-
cells, osteosarcoma cells, pancreatic islet tumour cells, thymus, Jurkat cells, helper 
T-cells and peripheral blood mononuclear cells. The function of cystatin F is 
important for specialized cells of the myeloid or T-cell lineage. 
Cystatin M 
Cystatin M was discovered in the primary tumour cell line.It is synthesized as a 
precursor protein and is secreted (Von Heinjie, 1985). The predicted molecular 
mass is approximately 14.3KDa and pi of 7.8 for the mature protein. A single 
disulphide bond is present (Sotiropoulou et al., 1997). An N-glycosylated form of 
cystatin M of 20-22 KDa was co-immunoprecipitated and accounted for about 
30-40% of total cystatin M protein. Both forms of native cystatin M occurred 
intracellularly. 
Cystatin M resembles other members of the family in having the three conserved 
domains. Cystatin M has 40% homology to human family 2 cystatins(Sotiropoulou 
et al.,1997). The overall homology between cystatin M and other cystatins range 
from 30-40% for conserved amino acid residues and 25 to 33% for identical 
amino acids. Cystatin M shows the closest homology to cystatin C, they share 
33% identical and 38% conserved amino acid residues. 
Cystatin M is expressed by normal mammary epithelial cells and a variety of 
human tissues but is not expressed in many metastatic mammary tumour cell 
lines. High levels of cystatin M are present in placenta, lung, skeletal muscle, 
kidney and pancreas. Lower level was observed in heart tissue. 
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Table 1.1 summarises the various mammalian and non-mammalian sources from 
where low Mr CPI have been isolated. 
EVOLUTIONARY RELATIONSHIP 
Statistical analysis (Barker and Dayhoff, 1972) of the similarities between the 
aligned sequence is suggestive that they have evolved from a single primitive 
sequence. Difference matrix of sequence of the members of superfamily revealed 
that the type I form one family and type II cystatins form a second whereas 
kininogens also form a single family. 
However, members of the cystatin superfamily are closely related to each other. 
Figure 1.2 demonstrates the relationship between all known inhibitory active 
human cystatin domains according to their sequence homology and 
physicochemical properties. 
The structure of cystatin indicates that the members of the family involved atleast 
six duplications of genetic material from a single primordial sequence to produce 
the cystatins A, B, C, S and 3 segments of kininogens. Gene structure of 
kininogen (Kitamura et al., 1985) shows that each of the three cystatin like 
segments of kininogens is coded for by three exons for which, the cystatin gene 
was the precursor. Some workers reported that only the first two of the three 
exons of the primitive family 2 gene were represented in family 1 cystatin gene, 
the third segment is acquired during the evolution of family 2 cystatins (Keil-
Dlouha, 1986). Analysis of amino acid sequence data led to the conclusion that 
the differences in the length of the polypeptides are accounted for by insertion 
and deletion of the genetic material in small blocks (Salvesen et al., 1986). 
Since disulphide bonds are often acquired in the evolution of protein but rarely 
lost (Williams; 1982), it is assumed that the primitive precursor of the cystatin 
was not unlike a modern type I cystatin. 
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TABLE-1.1: LOW Mr CPI FROM OTHER SOURCES 
Source 
African pufF 
(Bitis arietus) 
Beef 
Bombyx mori 
Bovine 
Carp 
Cat 
Chum 
Salmon 
Dog 
Guinea pig 
Horse shoe 
Crab 
Hog 
Human 
Litomosoides 
sigmodontis 
Paramoecmni 
caudatiim 
Rabbit 
Rat 
Tetrahymena 
pyriformis 
[ Trypanosoma 
i cnizi 
Tissue 
Adder 
Nasal & 
articular 
cartilage 
spleen 
Hemolymph 
Brain 
Hoof 
Muscle 
Colostrum 
Ovary 
Skin 
Egg 
Colostrum 
Parotid gland 
Kidney 
Skin 
Hemocytes 
Kidney 
Liver 
Placenta 
Squamous 
Mr 
13,000 
13,000 
-
25,000 
11,000 
11,406 
14,000 
14,300 
12,787 
12,000 
-
-
-
& 
-
12,600 
-
12,400 
12,300 
-
cell carcinomata 
Spleen 
-
-
Liver 
Skin 
Brain 
-
-
11,400 
12,000 
14,000 
-
5000-10,000 
12,500 
12,500 
-
-
11.000 
pi 
6.5 
4.8-7.0 
-
4.7 
5.23 
-
6.2 
10.0-10.3 
-
acidic 
-
-
-
acidic 
-
-
-
-
4.7-5.0 
6.0-6.5 
-
-
-
6.6 
-
-
-
Reference 
Evans and Barrett, 1987 
Roughley et a l , 1978 
Brzin et al., 1982 
Yamamoto et al., 1999 
Aghajanyan et al., 1996 
Tsushima et al., 1996 
Bige et al., 1985 
Zabari et al., 1993 
Hirado et al., 1984 
Tsai et al., 1996 
Jarvinen, 1976 
Yamashita and Konagawa, 
1996. 
Poulik et al., 1981 
Sekine and Poulik, 1982 
Jarvinen, 1976. 
Agarwala et al., 1996 
Lenney et al., 1979 
Green et al., 1984 
Warwas & Bamicki, 1985 
Rinnie et al., 1980 
Jarvinen and Rinnie, 1982 
Plaff et al., 2002 
Lenney et al., 1979 
Pontremoli et al., 1983 
Udaka & Hayashi, 1965 
Hayashi, 1975; Tokaji, 1971 
Kopitar et al., 1983 
Lenney et al., 1979 
Montciro ct al., 2001 
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Figure 1.2 Schematic illustration of evolutionary relationship 
The evolutionary relationships between all known inhibitory active 
human cystatin families. 
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Cystatin A 
Cystatin B 
Cystatin S 
Cystatin SA 
Cystatin SN 
Cystatin C 
Cystatin D 
Cystatin E/M 
Cystatin F 
Kininogen D3 
Kinlnogen D2 
Type I 
Type II 
Type ill 
The evolutionary relationship among the various CPIs remained largely obscure 
until Muller-Esterl et al (1985) suggested a common evolutionary origin of stefms, 
cystatins and kininogens. Their model has been constructed on the basis of 
sequence homology. Muller-Esterl proposed that the diversity of CPI has evolved 
from two ancestral building blocks A and B. The stefin progenitor represents the 
whole superfamily comprising a single A unit. Cystatin acquired a second element 
B, possibly by gene fusion thus forming AB unit. Gene triplication of the 
archetypal inhibitor generated the kininogen heavy chain which contains three 
cystatin like copies (AB)^. Hence, the superfamily of mammalian CPI is 
constituted by atleast three distinct families with stefin, cystatin and kininogens as 
their prototypes. 
The phylogenetic dendogram depicts the divergence between chicken cystatin and 
human cystatin C and S occurred 300 million years ago, the time of appearance 
of first reptile. The appearance of the first mammals about 90 million years ago 
coincides with the divergence of human cystatin A and rat cystatin a and cystatin 
C and S. The divergence of human and rat cystatin B(P) correspond to the time 
of the oldest known placental mammals, about 80 million years ago. The 
divergence of cystatin A and B appears to be about 230 million years ago, 
before the appearance of true mammals. 
STRUCTURE 
Amino Acid Composition of the Cystatins 
All known members of the cystatin superfamily are polypeptides of 98-126 amino 
acid residues with Mr values falling in the range 11,000-14,000 (Table 1.2). It 
can be seen that cystatins A and a are devoid of cysteine whereas cystatins B 
and (3 contain one and two residues, respectively. Type 11 cystatins contain four 
cysteine residues however, cystatin F is reported to have two more cysteine 
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TABLE-1.2: AMINO ACID COMPOSITION OF CYSTATINS 
Data are calculated from published amino acid sequence for Type 1 and 2. 
AA 
Cys 
Ser 
Thr 
Pro 
Ala 
Gly 
An 
Asp 
Glu 
Gin 
His 
Arg 
Lys 
Met 
lie 
Leu 
Vol 
Phe 
Tyr 
Trp. 
Total 
Human 
cyst 
A 
-
2 
7 
5 
5 
8 
5 
6 
9 
6 
1 
1 
12 
2 
4 
8 
9 
2 
6 
-
98 
TVpe I 
Human 
cyst 
B 
1 
6 
7 
5 
8 
3 
5 
4 
6 
7 
5 
2 
9 
2 
2 
6 
9 
7 
4 
-
98 
Bovine 
stefln 
C 
-
5 
5 
4 
7 
4 
5 
7 
8 
7 
5 
3 
9 
2 
4 
6 
11 
7 
3 
1 
101 
Cyst 
C 
4 
9 
7 
8 
10 
8 
5 
7 
5 
7 
5 
8 
7 
3 
2 
8 
10 
5 
4 
-
122 
Type n 
Cyst 
S 
4 
5 
5 
5 
7 
5 
4 
8 
12 
8 
2 
8 
4 
1 
6 
8 
7 
6 
6 
2 
113 
Chicken 
Cyst 
4 
12 
5 
5 
7 
5 
4 
6 
9 
7 
1 
8 
7 
2 
6 
10 
9 
3 
5 
1 
116 
Cyst 
F 
6 
6 
9 
5 
3 
4 
7 
5 
6 
6 
4 
7 
10 
2 
4 
12 
11 
6 
3 
2 
118 
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residues apart from the usual four cysteine residues. Although tryptophan is absent 
from type I cystatins, it is reported to be present in stefin C. 
An interesting feature in stefin B is the difference in the conserved QVVAG 
region in the stefins of mammalian origin: Val 54 is replaced with Leu 54. Grubb 
et al (1984a) identified the disulphide linked peptides from human cystatin C and 
chicken cystatin between Cys 71-Cys 81 and Cys 95-Cys 115. Anastasi et al 
(1983) found that cystatin contain no free thiol group. 
Cystatin E apart from other usual conserved sequences characteristic of family 2 
cystatins has a five residue insertion between amino acid 76 and 77 and a 
deletion of residue 91 (cystatin C numbering). Ni et al (1998) deciphered the 
presence of a second Trp residue, in addition to the conserved Trp-106 in 
cystatin F. 
Secondary Structure 
The structure of chicken cystatin and human cystatin C has been studied 
extensively. On line of evidence from analysis of amino acid sequence for the 
distribution of hydrophilic and hydrophobic residues, the predicted hydrophilic 
residues are considered to be on the surface whereas hydrophobic regions are 
internal. 
Each sequence possess a large N-terminal hydrophilic region (15-42 residues) and 
a prominent central hydrophobic region (55-70) followed by another large 
hydrophilic region at C-terminus. The secondary structure of human cystatin C in 
solution is very similar to that reported for chicken cystatin (Dieckmann et al., 
1992) and the crystalline form of chicken cystatin has been reported by Bode et 
al (1988). 
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Both human cystatin C and chicken cystatin as well as the family 1 cystatins (A 
and B) (Martin et al., 1994; 1995; Stubbs et al., 1990) consist of five stranded 
antiparallel |3-pleated sheet which is wrapped around a straight five turn a-helix 
(Figure 1.3). An appending segment of partial a-helical geometry is present in 
chicken cystatin (Saxena and Tayyab, 1997) which was not found in human 
cystatin C by X-ray diffraction (Bode et al., 1988). The conformation of this 
region seems to be closer to that found for chicken cystatin in solution which 
consists of two loops (Dieckmann et al., 1993). The N-terminal segment upto Val 
10 seems to be flexible similar to that of other cystatins (Dieckmann et al., 1993; 
Martin et al., 1995). Trp was found only in the second hairpin loop of cystatins 
(Bode et al., 1988). 
Circular dichroism and computer prediction of secondary structure from the 
sequence indicate that chicken cystatin has about 20% a-helix, 42% p-structure 
and 24% p-tum and 12% random coil (Schwabe et al., 1984). 
Ekiel and Abrahamson (1996) and Janowski et al (2001) proposed that human 
cystatin C undergoes dimerization under mild denaturing conditions. NMR studies 
revealed that the majority of the protein is not affected by dimerization however, 
the CP binding site is significantly affected (Ekiel et al., 1997) which accounts for 
the activity loss (Abrahamson, 2001). Hence, it is concluded that hydrophobic CP 
binding site is involved in the monomer-monomer contact.The dimerization may be 
relevant to regulation of cystatin C inhibitory activity in vivo (Abrahamson, 2001). 
Three dimensional swapping studies indicate the dimerization of human cystatin C 
to be a step towards protein oligomerization (Janowski et al., 2001). 
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Figure 1.3 3D structure of a typical type II cystatin and its secondary 
structure elements 
The structure contains a large proportion of P-strands, which form 
a P-pleated sheet that is wrapped around a central a-helix, 
N-terminal is exposed to the surface. Letters represent the 
conserved amino acid residues in the binding surface. 
23 

INHIBITION OF PROTEASES 
Specificity 
All the enzymes known to be inhibited by the cystatins are proteases with 
cysteine at active sites. No example of serine, aspartic or metallo-proteinase or 
non-proteolytic enzymes being inhibited by cystatins is available. Tests that have 
been reported include those on cystatin A and B with trypsin, chymotrypsin, 
pancreatic elastase, cathepsin G and thermolysin (Fraki, 1976; Green et al., 1984). 
The available data indicates that all cystatins inhibit CP of papain superfamily 
including papain, chymopapain, papaya proteinase III, ficin, actinidin and the 
lysosomal CP, cathepsin B, H and L. 
Of the type II cystatins, chicken cystatin has been shown to inhibit papain, ficin, 
chymopapain, papaya proteinase III, actinidin and cathepsin B, H, L and N 
(Possum and Whitaker, 1968; Keilova and Tomasek, 1974; 1975; Barrett, 1985; 
Etherington, 1976), cystatin S inhibits papain and ficin (Isemura et al., 1984b); 
beef colostrum cystatin inhibits papain and cathepsins B and H (Hirado et al., 
1984).Cystatin M inhibits papain (Sotiropoulou et al., 1997). Papain and cathepsin 
B are inhibited by cystatin E (Ni et al., 1997). Cystatin F inhibits papain and 
cathepsin L but not cathepsin B (Ni et al., 1998) and cystatin D inhibits 
cathepsin L, H and S but not cathepsin B (Balbin et al., 1994). 
Ironically, papain homologue from pineapple bromelain, is not inhibited by cystatin. 
The low Mr cystatins do not inhibit the calpains (cystatin B: Kominami et al., 
1982b; chicken cystatin: Johnson et al., 1984; human amniotic fluid cystatin: 
Rohrlich et al., 1985). 
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Partial inhibition of clostripain by human cystatin A and chicken cystatin but no 
inhibition of streptococcal cysteine proteinase were reported by Green et al 
(1984). Clostripain was not inhibited by cystatin S (Isemura et al., 1984b). 
Cystatins also inhibit exopeptidases. Keilova and Tomasek (1975) showed that 
chicken cystatin inhibits dipeptidyl peptidase I. This proteinase is also known to 
be inhibited by human cystatin A, B, C and S (Green et al., 1984; Barrett et al., 
1984a; Isemura et al., 1986), cystatin a (Jarvinen and Hopsu-Havu, 1975) and 
cystatin P (Kominami et al., 1982a). Inhibition of lysosomal carboxypeptidase B 
by cystatin P was reported by Kominami et al (1982a). 
Kinetic Beliaviour 
The cystatins are the first group of protein inhibitors of CP for which the 
mechanism of inhibition has been investigated. Cystatins are a group of potent, 
non covalent and reversible inhibitors of CP of papain superfamily (Barrett, 1987; 
Ekiel et al., 1997).Some of the reported values of Ki are presented in Table-1.3a. 
It can be seen that the inhibition constants extend down atleast as far as 5x10 
'^M. Inhibition of cathepsin B tends to be weaker than that of papain and 
cathepsin H and L, except with cystatin C which is a strong inhibitor of 
cathepsin B. 
Some estimates of individual association and dissociation rate constants are 
available in Table-1.3b. 
Reactive site 
The reactive site of the folded, native cystatin molecule could obviously involve 
parts of the molecule well separated in primary sequence. The elucidation of the 
crystallographic structure of cystatin/enzyme complexes classified the precise 
location of the reactive site. 
TABLE-1.3a: Ki VALUES FOR INHIBITION OF CF BY LOW Mr 
CYSTATIN 
Papain 
Cath.B 
Cath.H 
CathX 
Dipeptidyl 
peptidase I 
Cath S 
A-
0.019 
8.2 
0.31 
1.3 
33 
nd 
B" 
0.12 
73 
0.58 
0.23 
0.23 
nd 
C 
0.005 
0.25 
0.28 
0.005 
3.5 
nd 
D" 
0.9 
1000 
8.5 
25 
nd 
0.24 
F' 
1.1 
-
-
0.31 
nd 
nd 
E" 
0.39 
32 
nd 
nd 
nd 
nd 
Chicken 
cyst. 
0.005 
1.7 
0.064 
0.019 
nd 
0.35 
Bovine 
stefin 
0.18 
>100 
nd 
0.0065 
nd 
nd 
Puff 
adder 
0.1 
2.7 
nd 
nd 
0.23 
nd 
TABLE-1.3b: RATE CONSTANTS FOR INTERACTION OF CYSTATINS 
WITH THIOL PROTEASES 
Enzyme 
Papain 
Cath.B 
Ficin 
Cath.H 
Dipeptidyl 
peptidase 1 
Inhibitor 
Chicken cystatin 
Bovine cystatin B 
Bovine Stefin C 
Chicken cystatin 
Chicken, cystatin 
Bovine Stefin A 
Chicken cystatin 
K 
• ts 
1x10' 
6.3x10* 
1.8x10* 
1.4x10* 
4.3x10* 
1.0x10' 
^ d U . 
<5.Ox 10-5 
7.7x10-^ 
-
2.3x10-3 
nd 
2.2x10-3 
Reference 
Nicklin & Barrett, 
Nicklin & Barrett, 
Nicklin & Barrett, 
Nicklin & Barrett, 
Sen & Whitaker, 
Nicklin & Barett, 
1984 
1984 
1984 
1984 
1973 
1984 
Values are given in nanomolar concentration. 
nd - not determined. 
a Barrett et al.. 1984a; Gounaris et al., 1984; Salvesen et al.. 1985 and Machleidt et al. 
b 
c 
d 
1986. 
Balbin et a!.. 1994 
Ni et al.. 1998 
Ni et al.. 1997 
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The central region of the sequence contains the highly conserved block, usually 
Gln-Val-Ala-Gly at 53-57, Gin 53 and Gly 57 are common to all the cystatins 
and inhibitory kininogen segments and neighbouring residues also show strong 
tendency to conserve this type of sequence. In chicken cystatin the sequence is 
QLVSG instead of QWAG (Barrett et al., 1986; Barrett, 1987). Residues 60-62 
are all uncharged generally with large hydrophobic side chains in the small 
cystatins. 
The C-terminal part of the sequence tend to be very varied, although Cys 71 
and Tyr 100 are conserved in the large majority of sequences. There also appear 
to be deletions and insertions in the C-terminal segments that suggest variability in 
structure but the disulphide bonds presumably stabilize the folding of these 
segments in cystatins of types II and III. Chicken cystatin has Trp 104 as the 
reactive group during the interaction with CP. All other type II cystatins also 
contain the conserved second hairpin loop around Trp 104. 
Estrada et al (1998) emphasized the role of Gly 4 of human stefin A (cystatin 
A) in the binding of target proteinases. Even the smallest replacement by site 
directed mutagenesis by Ala resulted in approximately 1000, 10 and 6000-fold 
decreased affinities for papain, cathepsin L and cathepsin B, respectively. As the 
side chain of the substituted amino acid residue became more bulky, the inhibitory 
activity of the variant markedly decreased (Shibuya et al., 1995). 
The single cysteine residue, Cys 3 of human and bovine cystatin B has 
appreciable importance for inhibition of CP in particular, cathepsin B (Pol & 
Bjork, 2001). The contact residues in the second hairpin loop. Leu 73 and His-
75 were replaced by Gly and resulted in appreciably reduced affinities for papain 
and cathepsins H and B. These two residues contribute 20-30% of the free 
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energy of binding of cystatin B (Pol and Bjork, 1999). Replacement of the 
contact residue in the C-terminal end, Tyr-97, with Ala resulted in loss in affinity 
for papain and cathepsins H and L. All affinity decreases were due to increased 
dissociation rate constants (Pol & Bjork, 1999). 
Cystatin forms tight equimolar complexes with CP (Anastasi et al., 1983; Nicklin 
and Barrett, 1984). Kominami et al (1982b) concluded that the binding ratio 
between cystatin 3 and rat cathepsin H is 1:1 on the basis of titration of the 
active site of proteinase and studies of the complex on SDS PAGE. Abrahamson 
et al (1987) also reported the rapid formation of 1:1 complex between cystatin C 
and papain. Previous studies of chicken cystatin revealed that about two molecules 
of the inhibitor are required for the inhibition of each molecule of papain (Nicklin 
& Barrett, 1984; Bjork et al., 1989). Nicklin and Barrett (1984) found that 
dipeptidyl peptidase I and papain competed for binding to single binding site of 
cystatin, contrary to a previous report. In separate experiment cathepsin B was 
shown to compete for binding to the same site too. 
MECHANISM OF INTERACTION OF CYSTATINS WITH PROTEASES 
It has been established that no disulphide bond is formed between the active site 
cysteine and the inhibitor because complexes dissociate when denatured without 
reduction (chicken cystatin: Nicklin and Barrett, 1984; kininogens: Gounaris et al., 
1984) and carboxymethylation of enzyme and inhibitor does not prevent complex 
formation (Anastasi et al., 1983). It became clear that complex formation is 
reversible competitive and non-covalent with substrate.The nature of interaction 
resemble standard mechanism of inhibition described by Laskowski and Kato 
(1980). The active site of papain in complex with chicken cystatin is unreactive 
with 5,5-dithio-bis- (2-nitrobenzoic acid) at pH 8, 2,2' - dipyridyl disulphite at pH 
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4 and iodo ['•*€] acetate (Nicklin and Barrett, 1984).The complex formation is 
accompanied by pronounced spectroscopic changes, most Hkely reflecting local 
perturbation of the environment of aromatic residues in both enzyme and inhibitor 
(Lindahl et al., 1988; Bjork et al., 1989). 
The mechanism of inhibition of papain by chicken egg white cystatin has been 
extensively studied. Bode et al (1988) proposed a model for the interaction of 
cystatin with CP based on X-ray crystal structure of the Gly-form of chicken 
cystatin and subsequent studies based on docking experiment. Three parts of the 
inhibitor are in close contact with the active site cleft of papain, the amino 
terminus with conserved Gly-9, a first hairpin loop (53-57) containing the 
prototype sequence, QVVAG (Barrett et al., 1986; Barrett, 1987) and a second 
hairpin loop (residues 102-107) containing conserved Trp 104. Bode et al (1988) 
demonstrated that the major contribution is from the first hairpin loop containing 
the QVVAG sequence (Turk, 1985; Ohkubo et al., 1984). According to the 
model the N-terminal segment of cystatin which is more flexible bridges over the 
active site Cys 25 residue of papain without completely burying it and additionally 
the side chain of Leu 8 binds to the S^ subsite of papain which determines the 
substrate specificity of papain (Drenth et al., 1976; Asboth et al., 1988). The side 
chain groups of QLVSG segment makes the most intimate contacts with putative 
S, subsite of papain, Figure-1.4. This explains the presence of Gly 9 in close 
vicinity of but not in direct contact with Cys 25 of papain. Removal of Leu 7 
and Leu 8 leads to an approximately 5000 fold lower afiinity for papain. 
This was supported by Brzin et al (1984) who demonstrated that the truncated 
form of human cystatin C starting with Leu-Val before Gly-11 (corresponding to 
Gly-9 of chicken cystatin) has virtually the same affinity for papain as the fijU 
length form whereas the truncated form starting with Gly 12 has been reported 
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Figure 1.4 Scheme of the proposed model for the interaction of chicken 
cystatin with papain 
Interaction of chicken cystatin with papain has been illustrated. 
VI2 
• HN 
R52 CYSTAHN 
Q116 
to be 1000 fold weaker inhibitor (Abrahamson et al., 1987). However, Nycander 
and Bjork (1990) emphasized the role of Trp-104 in the inhibition of CP. 
According to their model, Trp 104 of cystatin interacts primarily with two 
tryptophan side chains in the active site cleft of papain, Trp 177 and Trp 181, in 
such a manner that the indole ring of Trp 104 stacks on the side chain of Trp 
177 and lies edge on the indole ring of Trp 181. 
A two step mechanism of inhibition of the lysosomal CP, cathepsin B by its 
endogenous inhibitor, cystatin C was observed by Nycander et al (1998). An 
initial weak interaction in which N-terminal of the inhibitor binds to the proteinase 
is followed by a conformational change. Subsequently, the occluding loop of the 
proteinase that partially obscures the active site is displaced by the inhibitor 
bringing about another conformational change. The presence of the occluding loop 
of cathepsin B renders it much less susceptible to inhibition by cystatins than 
other proteinases. A similar two step binding of cystatin A to the CP was 
suggested by Estrada and Bjork (2000). The flexible N-terminal region of the 
cystatin binds independently to the target proteinases after the hairpin loops. 
FAMILY 3 (TYPE HI): KININOGENS 
In mammals, three types of kininogens have been found differing in size, structure 
and function. The largest kinin precursor, commonly referred to as high 
molecular weight (HMW) kininogen, has an Mr of 88000-114000, depending on 
its species origin (Kato et al., 1981). Among the smaller kininogens, a low 
molecular weight (LMW) kininogen with an Mr of 50000-68000 is found 
throughout the mammalian lineage (MuUer-Esterl et al.,1986).The third type, T-
kininogen of Mr 68000, seems to be unique to the rat (Okamoto and 
Greenbaum, ]983). The various types of kininogen have the same basic 
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structure: a heavy chain of 50-60KDa at the amino-terminus, the kinin segment in 
the core part of the molecules and the light chain of variable length at the 
carboxy-terminus (Kitamure et al., 1983; Nawa et al., 1983; Lottspeich et al., 
1985). The primary structure of the heavy chain, kinin section and a segment of 
12 amino acids are identical in HMW and LMW kininogens, but the structure of 
their light chains diverge considerably. HMW kininogen has a large light chain of 
45-58 KDa which harbours a unique histidine-rich region (Sugo et al., 1980). 
The HMW kininogen light chain contains the binding site for prekallikrein and 
factor XI. The structure of T-kininogen closely resumbles that of LMW kininogen 
in its heavy and light chain portions (Furuto-Kato et al., 1985; Cole et al., 1985) 
but differs at the amino-terminal flanking region of the kinin segment. 
The primary site of kininogen biosynthesis is the liver with only minor expression 
in other tissues. The kininogens are secretory proteins synthesized with signal 
peptide and undergo glycosylation. Kininogens serve as substrates for the 
kallikrein-like enzymes and release the kinins, they bind coagulation proenzymes 
and assemble them on the contact phase and they inhibit cysteine proteinases and 
form inactive enzyme-inhibitor complex (Muller-Esterl et al., 1986). pi values 
reported for the multiple isoelectric forms of L and H kininogens fall in the 
range 4.0-4.9 (Ryley, 1979; Muller-Esterl et al., 1982; 1983; Kato et al., 1981). 
The proteins are stable to temperature in the range 50-90^0 (Sasaki et al., 1981; 
Taniguchi et al., 1981). 
Plasma concentration of kininogens have been determined by radio immuno assay 
to be 109-272 |ag/ml (L-kininogens) and 69- 116 |ig/ml (H-kininogen) (Adam et 
al., 1985). Plasma concentration of a CPI have been reported as 425 |ig/ml 
(Ryley, 1979) and 359 jig/ml (Gounaris et al., 1984). 
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Kitamura et al (1985) and Salvesen et al (1985) found that three cystatin like 
segments are present, although the first lacks the Gln-Val-Val-Ala Gly sequence. It 
is known that the LMW-kininogen contain no free thiol groups (Salvesen et al., 
1985). 
Kininogens inhibit papain, ficin, cathepsin B, H and L (Jarvinen, 1979; Minakata 
et al., 1982; Pagano and Engler, 1982; Iwata et al., 1982; Gounans et al., 1984). 
BIOLOGICAL ROLE 
The present knowledge of serine proteinases and their endogenous inhibitors at 
the molecular level is much more detailed than is our understanding of the 
structure and physiological functions of thiol proteinases. Since cystatins constitute 
a powerful regulatory system for endogenous cysteine proteinases, which are often 
secreted or leaking from the lysosomes of dying or diseased cells (Ekiel et al., 
1997) which otherwise may cause uncontrolled proteolysis and tissue damage. It 
is established that imbalance between these endogenous inhibitors and thiol 
proteinases have been associated with different diseases. Thiol proteinase activity 
cannot normally be measured in body fluids, but can be detected extracellularly in 
conditions like endotoxin induced sepsis (Abrahamson, 1994), metastasizing cancer 
(Koppel et al., 1994) and local inflammatory processes such as rheumatoid 
arthritis (Gabrijeleic et al., 1990; Trabandt et al., 1991), purulent bronchiectasis 
(Buttle et al., 1990) and periondontitis (Cox and Eley, 1989; Lah et al., 1993), 
renal failure (Kabanda et al., 1995), Alzheimer's disease (Nakamura et al., 1991), 
multiple sclerosis (Bever et al., 1995), muscular dystrophy (Sohar et al., 1988) 
which indicates that a tight enzyme regulation by cystatins is a necessity in the 
normal state. 
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Cystatin B(3) serve general protective role. The abundance of cystatin A 
selectively in squamous epithelial cells and PMN leucocytes (Kotyza & Krepela, 
2002) contrasts strongly with the general distribution of cystatin B and suggests a 
specific function connected with these types of cells. These cells are in the front 
line of defence against invading pathogens and parasites, many of which use CP 
in entering the body (North, 1982). A cysteine proteinase produced by 
Leishmania spp. is inhibited by human cystatin A, B and C and kininogens 
(Barrett and Coombs, unpublished data). 
Apart from defensive role, it is possible that cystatin A is involved directly in the 
physiology and pathology of the skin. Jarvinen et al (1978) suggested that the 
inhibitor may contribute to the keratinization process and Hibino et al (1980b) 
demonstrated production of cystatin a in the upper spinous or granular cells that 
became keratinized. Fukuyama et al (1982) have also suggested that cystatin a is 
involved in the differentiation of the epidermis on the basis of electron microscope 
immunolocalization work. Hopsu-Havu et al (1981) demonstrated autoantibodies to 
cystatin A in patients with a wide variety of dermatological conditions like 
dermatitis and psoriasis. Autoantibodies may be produced when the inhibitor leaks 
into the blood stream following damage to the epidermis and dermis. 
Cystatins have also been implicated in other inflammatory reactions in the skin 
(Udaka,1965; Hayashi et al.,1965). 
Alaviakko et al (1985) reported that one or two cases of AIDS showed profound 
alterations of dendritic reticulum cells revealed by localization of cystatin A. 
A role of type I cystatins has also been considered in connection with the control 
of turnover of myofibrils in the cytoplasm of muscle fibres. The degradation of 
myofibrils in the cytoplasm of muscle cells is probably mediated by CP and can 
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be modified by low Mr inhibitors. Spanier and Bird (1982) indicated that levels 
of cystatins decrease in the guinea pigs with a nutritional muscular dystrophy 
induced by vitamin E deficiency. 
Cystatin A level increases in patients with cardiovascular disease, sarcoidosis and 
hepatic cirrhosis (Hopsu-Havu et al., 1983b). The concentration of cystatin B 
increases in patients suffering from inflammatory diseases and kidney failure 
(Hopsu-Havu et al., 1982; 1985a). 
Some reports tend to implicate lysosomal CP in the malignancy suggesting that 
they may contribute to the nutrition of tumour cells, to the destruction of 
connective tissue elements in invasion and sloughing off" of metastatic cells into 
the circulation (Poole, 1973; Strauli et al., 1980; Sloane & Honn, 1984). 
Furthermore, the role of cathepsins and their inhibitors in various types of cancers 
has been investigated (Sloane et al., 1994; Catkins et al., 1995; Kos et al., 1996). 
Nishida et al (1984) have reported that cells of one human malignant melanoma 
cell line released cystatin like inhibitor into their culture medium. On the contrary, 
a deficiency state in which the levels of the intracellular cystatin B are lowered 
due to mutations has been shown to segregate with a form of progressive 
myeclonus epilepsy (Pennacchi et al., 1996). 
Recent observations indicate that some pathogens produce proteins homologous to 
cystatins that are capable of suppressing the host immune response against the 
pathogen through interferring with the MHC class II- restricted antigen processing 
in the antigen presenting cells of infected host. This type of pathogen induced 
immunosuppression is exemplified by Bm-CPI-2 protein, a cystatin homologue 
secreted by the filarial parasite Bnigia malayi, which inhibits the MHC class II-
restricted antigen processing via direct inhibition of multiple lysosomal cysteine 
proteases including cathepsins S, L and B and legumain (Manoury et al., 2001), 
The concentration of cystatin C may be elevated in the serum of patients 
suflfering from autoimmune diseases, lupus erythematosus and glomerulonephritis 
(Brzin et al., 1984). 
Certain genetic disorders are linked to mutation in cystatin gene. In Icelandic 
hereditary cystatin C amyloid angiopathy, a mutation in the cystatin C gene 
(CSTC) causing a single substitution (L68Q) in cystatin C gene is coupled to 
decreased concentration of this major CPI in CSF, and leads to its amyloid 
deposition in almost all tissues including the cerebral arteries (Pennacchio et al., 
1998; Ghiso et al., 1986; Palsdottir et al., 1988; Cohen et al., 1983; Grubb, 
1990). This deposition results in fatal cerebral haemorrhages in young non-
hypertensive adults. 
Another pathological condition has been implicated due to a decrease in CSF 
cystatin C level i.e. Guillain-Barre syndrome, chronic inflammatory demyelinating 
poly-neuropathy and multiple sclerosis. In these groups of patients, high cathepsin 
B activity but not cathepsin H activity was observed in CSF (Nagai et al.,' 2000). 
Kos et al (1997) pointed out that cystatin C level in the sera of advanced 
melanoma patients increases owing to higher levels of cathepsin B and H in these 
patients. Differently truncated forms of cystatin C are found in the urine of 
patients with nephrological disorders (Popovic et al., 1990). 
Moreover, cystatins play additional roles in human defence by being the members 
of non-immune defence system of the body against microbial invasion (North et 
al., 1990). Cell culture shows that chicken cystatin, human cystatin C and D 
inhibit the replication of polio (Korant et al., 1985), herpes simplex (Bjork et al, 
1990) and coma virus (Collins and Grubb, 1991), respectively. Antibacterial 
activity of peptidyl derivative cyclopeptides structurally based upon the inhibitory 
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centre of human cystatin C was reported by Kasprzykowski et al (2000) against 
Streptococcus pyogenes and Staphylococcus aureus. Takahashi et al (1994) also 
reported the inhibition of Staphylococcus aureus V8 by phosphorylated cystatin a 
in the skin comified envelop. 
However, the resuhs obtained by Blankenvoorde et al (1998) suggested that the 
growth inhibition of Porphyromonas gingivalis is due to the antibacterial 
sequences present in chicken cystatin and cystatin S and that it does not depend 
on the inhibition of P. gingivalis CP. Antifungal role of cystatin from plant 
sources has also been reported (Soares-costa et al., 2002). 
Different reports suggest possible clinical application of these proteins for 
prediction of prognosis (Thomson et al, 1995; DuflEy et al., 1996). Serum cystatin 
C can be used as a marker of GFR in patients with various renal diseases 
(Newmann et al., 1995). 
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2. MATERIALS 
Chemicals used for the present study were obtained from the sources indicated. 
1. Gene I, Bangalore, India 
Molecular weight marker-PMW-M, Goat anti-rabbit IgG alkaline phosphatase 
conjugate. 
2. Hi-Media, India 
Agar agar, agarose, Freund's complete adjuvant, Freund's incomplete adjuvent, 
nutrient agar, nutrient broth, sodium azide. 
3. Merck, India 
Benzoyl-DL-arginine-p-nitroanilide hydrochloride (DL-BAPA), Papain. 
4. Pharmacia Fine Chemicals, Sweden 
Blue dextran, Sephadex G-75. 
5. Qualigens Fine Chemicals, India 
Acetone, ammonium persulfate, ammonium sulphate, bromophenol blue, cupric 
sulphate, cupric chloride,DMSO, disodium hydrogen phosphate, ethyl alcohol, 
glacial acetic acid, hydrochloric acid, isopropanol, mannitol, methanol, monosodium 
dihydrogen phosphate, potassium iodide, silver nitrate, sodium bicarbonate, sodium 
carbonate, sodium chloride, sodium formate, sodium hydroxide, sodium lauryl 
sulphate, sodium potassium tartarate, sodium thiosulfate, sulphuric acid, thiourea, 
trichloroacetic acid, TEMED, tris (hydroxymethyl amino methane), Tween-20. 
6. Sigma Chemicals Co. USA 
Bromelain, ficin, pepsin, ovalbumin, PVDF membrane and CAPS buffer. 
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7. Sisco Research Lab (SRL), India 
Acrylamide, bis-acrylamide, bovine serum albumin, casein, chymotrypsin, L-cysteine, 
comassie brilliant blue-R250, cytochrome C, DEAE-cellulose, DTNB, EDTA, 
Folin's phenol reagent, GdnHCl, glycine, p-nitrophenyl phosphate, phenol, 
ribonuclease, riboflavin, sucrose and urea. 
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3. METHODS 
PURIFICATION OF GOAT KIDNEY CYSTATIN 
Fresh goat kidneys (lOOg) were collected from the abbatoir immediately after 
slaughter. The kidneys were homogenised in 1% (w/v) NaCl, 2% (v/v) butanol 
and 0.2M EDTA at 4°C. The supernatant was collected by centrifugation at 
SOOOrpm at 4"C in a Beckman J-21 cooling centrifuge. 
Alkaline Treatment 
The supernatant obtained was subjected to alkaline pH of 10.0 by 3N NaOH and 
incubated at 3TC for lOmin. After the incubation, the pH of the supernatant was 
again brought to pH 7.5 using 2N HCl. The precipitated proteins were removed 
by centriftigation at SOOOrpm at 4°C in a Beckman J-21 cooling centrifuge. 
Ammonium Sulphate Fractionation 
The supernatant was fractionated with 50% saturation of ammonium sulphate with 
gentle stirring at 4"C. After 4-6h, the precipitate was removed by centrifugation at 
3000rpm for 15min and the supematent thus collected was made 80% saturated 
with ammonium sulphate. The solution was allowed to stand at 4°C for lOh, the 
precipitate recovered by centrifugation at 3000rpm for 20min and dissolved in 
15ml of 50mM sodium phosphate buffer, pH 7.5. The fraction was extensively 
dialysed against several changes of the same buffer at 4'^ C to remove ammonium 
sulphate. 
Gel Filtration Chromatography 
A Sephadex G-75 column was prepared as recommended by Peterson and Sober 
(1962). The gel was allowed to swell in sufficient amount of distilled water for 
3h in a boiling water bath. The gel fines were removed by suspending the gel in 
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two to four fold excess 0.05M sodium phosphate buffer, pH 7.5 and allowing 
90-95% of the gel to settle down. The remaining gel in supernatant was rapidly 
removed by suction. A glass column mounted on a sturdy vertical support was 
filled to one third of its length with operating buflfer in order to check leaks and 
flush air bubbles from the dead space. The deaerated gel slurry was then poured 
with the help of glass rod into the column with care to avoid generating air 
bubbles. The column was left standing overnight. Flow rate was increased 
gradually and after accomplishing a constant flow rate higher than that required 
for final elution, the column was adjusted to the required flow rate. The packed 
column was thoroughly washed with two bed volumes of operating buffer (0.05M 
sodium phosphate buffer, pH 7.5). In order to check uniform packing and to 
determine the void volume of the column, 2% (w/v) solution of blue dextran in 
0.05M sodium phosphate buffer, pH 7.5 was passed through the column. The 
volume of blue dextran and protein solution applied was not more than 2-3% of 
the total bed volume. Five millilitre fractions were collected and assayed for 
protein and cystatin activity. Homogeneity of the preparation was analysed by 
10% PAGE. 
Ion-Exchange Chromatography 
Appropriate amount of DEAE-cellulose was suspended wdth 15 volumes of 0.5N 
hydrochloric acid for half an hour with constant stirring and washed in a Buchner 
funnel. The washing was continued till the pH of the filtrate was approximately 
equal to 7.0. The exchanger was then treated with 15 volumes of 0.5N sodium 
hydroxide for half an hour and washing continued till the pH of the filtrate 
approached neutrality. The DEAE-cellulose was then resuspended in operating 
buffer (0.05M sodium phosphate buffer, pH 8.5) to get a homogenous slurry. This 
slurry was poured on a vertically mounted glass column plugged with glass wool 
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with the help of a glass rod. The column was left standing for one hour. Flow 
rate was subsequently adjusted with the help of stop cock until constant rate of 
flow higher than required for final elution reached. Finally the required flow rate 
was adjusted. The column was then equilibrated with excess of the operating 
buffer till the pH of the effluent was identical to that of the eluting buffer. 
Elution was performed with a linear gradient (0-0:3M) of sodium chloride in 
0.05M sodium phosphate buffer, pH 7.5. Pooled fractions after gel filtration 
having protein and activity were loaded. Three millilitre fractions were collected 
and assayed for inhibitory activity and protein concentration. 
COLORIMETRIC ANALYSIS 
Determination of Protein Concentration 
Protein was estimated by the method of Lowry et al (1951). Aliquots of protein 
solution were taken in a set of tubes and final volume was made upto 1ml with 
distilled water. Five ml of alkaline copper reagent (containing one part of 1% (w/ 
v) copper sulphate and 2%(w/v) sodium potassium tartarate in 1% (w/v) sodium 
hydroxide and sodium carbonate) was added followed after lOmin of incubation at 
room temperature with 0.5ml of l.ON Folin-Ciocalteu's phenol reagent. The tube 
were instantly vortexed. The colour developed was read at 660nm after 30min 
against a reagent blank. A standard curve was prepared using BSA. 
Protein in the column fractions was monitored at 280nm in Spectronic-D21 
spectrophotometer. 
Carbohydrate Estimation 
The procedure described by Dubois (1956) was followed. Two millilitre aliquots 
containing 10-70|ig of carbohydrate was pipetted into a test tube and 0.05ml 
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80% phenol added. This was followed by the addition of 0.5 ml of concentrated 
sulphuric acid, the stream of acid being directed against the liquid surface rather 
than against the side of the test tube in order to obtain good mixing. The tubes 
were allowed to stand for lOmin thoroughly mixed and again incubated for 20min 
at 30°C. The colour intensity was measured at 490nm for the quantitation of 
hexose content. Glucose was used as the standard. 
Thiol Group Estimation 
The procedure described by EUman (1959) was followed for estimating the thiol 
groups of cystatin. SDS and p-mercaptoethanol induced appearance of free thiol 
group in the cystatin was followed by titration with DTNB reagent. Appropriate 
aliquots of 0.2ml native, SDS and P-mercaptoethanol treated cystatin were mixed 
with 0.1ml of DTNB reagent (prepared by dissolving 40mg in 100ml of 0.05M 
Tris-EDTA buffer, pH 8.0) in a total volume of 3.1ml. The absorbance was read 
after 15min at 412nm in Spectronic-D21 spectrophotometer. Free thiol 
concentration was calculated from the absorbance using molar extinction coefficient 
of 13,600M"'cm' for the thionitrobenzoic acid group released. A standard plot 
was prepared using cysteine. 
Assay of Cystatin Inhibitory Activity 
Caseinolytic assay for papain 
Inhibitory assay of cystatin was performed as described by Kunitz (1947). Kidney 
cystatin was examined for its ability to prevent thiol proteinases from digesting 
casein. For determination of inhibitory activity, papain was activated in the 
presence of 0.2M EDTA and 0.5M cysteine for lOmin prior to incubation of 
papain cystatin complex for 30min at 37°C in 0.05M sodium phosphate buffer, pH 
7.5. The enzyme inhibitor complex was further incubated with casein for 30min at 
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37°C and reaction stopped by the addition of 10% TCA. Acid insoluble material 
was removed by centrifugation at 2500rpm for 15min. The supernatent was 
analyzed for acid soluble peptides with Folin's phenol reagent as described by 
Lowry et al (1951). Ficin inhibition was also assayed by similar method. 
Amidase Assay for Papain 
Papain amidase activity was also measured as described by Ganrot (1966) by 
using chromogenic synthetic substrate DL-BAPA. Papain (O.lmg/ml) was activated 
in 20mM EDTA and SOmM cysteine at 37°C for lOmin. After incubation at 37"C, 
2.0ml freshly prepared BAPA solution (prepared by dissolving 5mg in 1.0ml 
DMSO and then the solution was brought to 11ml with phosphate buffer) was 
added and the volume was made upto 3.0ml with SOmM sodium phosphate 
buflfer, pH 7.5. The reaction was stopped by the addition of 0.5ml of 30% acetic 
acid and the absorbance of the yellow coloured p-nitroanilide formed was 
determined at 410nm. 
Assay of Caseinolytic Activity of Bromelain and Ficin 
The proteolytic activity of bromelain was measured according to the method of 
Murachi and Neurath (1960). The enzyme was activated at 37°C for lOmin in the 
presence of 20mM cystiene. Then the volume was made upto 1ml by sodium 
phosphate buffer, pH 6.0. One millilitre of 0.5% casein was added and incubated 
for 30min at 37"C. The reaction was stopped by 1.0ml 5% TCA. Acid insoluble 
material was removed by centrifugation at 2500rpm for 15min. The supernatant 
was analyzed for acid soluble peptides which were hydrolyzed by the enzyme by 
Folin's phenol reagent as described by Lowry et al (1951). 
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SLAB GEL ELECTROPHORESIS 
Polyacrylamide gel electrophoresis (PAGE) 
PAGE was performed by the tris-glycine system of Laemmli (1970) using the 
apparatus manufactured by Biotech, India. Concentrated stock solution of 30% 
acrylamide containing 0.8% bisacrylamide and 1.5M Tris, pH 8.8 were mixed in 
appropriate proportions to the required final concentration. It was then poured 
into the mould formed by the glass plates (8.5-10cm) separated by 1.5mm thick 
spacers. Bubbles and leaks were avoided. A comb providing template for 7 
sample wells was inserted into the stacking gel solution before polymerisation 
began. The polymerisation was complete in about 30min after which the comb 
was removed and wells overlaid with the running buffer. Routinely, a 10% 
acrylamide gel was used. Samples containing 20-40^g of protein were prepared to 
give a final concentration of 62.5mM Tris-HCl pH 6.8, 10% (v/v) glycerol and 
0.001% bromophenol blue as tracking dye. 
SDS Polyacrylamide Gel Electrophoresis (SDS PAGE) 
SDS PAGE was essentially performed by the method of Laemmli (1970). 
Concentrated stock solutions were mixed in appropriate order to give a final 
concentration of 10%. Protein samples were prepared in solution containing 
62.5mM tris-HCl pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) P-
mercaptoethanol and 0.001% (w/v) bromophenol blue. The samples were incubated 
at lOO^ C for 5min. Electrophoresis was performed at lOOV till the tracking dye 
reached the bottom of the gel. Running buffer used during electrophoresis 
contained 1% SDS in addition to 192mM glycine and 25mM Tris-HCl pH 6.8. 
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Staining of the Gel 
Commassie Blue Staining 
After electrophoresis, the gels were stained with five gel volumes of 0.25% 
commassie brilliant blue R-250 in 50% methanol and 10% acetic acid for at least 
4h. For destaining, the gels were incubated with shaking in 5% methanol and 
7.5% acetic acid at room temperature. 
Silver Staining of the Gel 
The gel after electrophoresis was silver stained by modified Blum's silver stain 
method (Nesterenko, 1994). The staining method was initiated by fixation for 
lOmins in 50% acetone, 1% trichloroacefic acid and 0.015% formaldehyde with 
subsequent washings. After a second fixation in 50% acetone only the gel was 
pretreated with 10% sodium thiosulfate and then impregnated with 20% silver 
nitrate and 37% formaldehyde. The protein bands were developed by immersing 
the gel in 2% sodium carbonate, 37% formaldehyde and 10% sodium thiosulfate 
for 30s to 1 min. The reaction was stopped by 1% glacial acetic acid and 
incubated for 15min in 1% glycerol after rinsing in distilled water. 
MOLECULAR WEIGHT DETERMINATION 
The molecular weight of goat cystatin was determined under native and 
denaturing conditions by gel filtration chromatography and SDS PAGE, 
respectively. 
The molecular weight of native goat cystatin was computed from its elution 
volume on a Sephadex G-75 column (2x70cm). The column was calibrated by 
determining the elution volume of some marker proteins-bovine serum albumin 
(68KDa), ovalbumin (45KDa), ribonuclease (12KDa) and cytochrome C 
(11.7KDa). This data was analyzed according to the theoretical treatment of 
Andrews (1964) method. The linear plot between Ve/Vo and logM was used in 
calculating the molecular weight of goat cystatin where V^  is the elution volume 
of the protein and V^  is the void volume of the column determined using blue 
dextran. 
Molecular weight of cystatin under denaturing conditions was calculated by the 
procedure of Weber and Osborn (1969) using SDS PAGE. The mobilities of 
marker proteins determined under identical conditions was plotted against the 
logarithms of molecular weight. The standard proteins used were phosphorylase b 
(97KDa), bovine serum albumin (68KDa), ovalbumin (45KDa) and carbonic 
anhydrase (29KDa) and soyabean trypsin inhibitor (20KDa). The analysis of data 
indicated a linear relationship between logM and relative mobility (Rm) and the 
plot was used in calculating the molecular weight of cystatin. 
IMMUNOLOGICAL PROCEDURES 
Immunization of Rabbits 
Antibodies against goat cystatin were raised in healthy male albino rabbits. 300|ig 
of electrophoretically pure cystatin in 0.5ml of normal saline emulsified with equal 
volume of Freund's complete adjuvant was injected simultaneously. Two weeks 
later 150|ag of cystatin was injected along with Freund's incomplete adjuvant. A 
similar second and third booster dose were given in the third and fourth week 
respectively and the animal was bled after an additional one week. The blood 
collected was allowed to coagulate at 22^0 for 3h. The antisera was 
decomplemented at 57"C for 30min and stored at -20"C in small aliquots. 
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Immunodiffusion 
Immunodiffusion was performed essentially by the method of Ouchterlony (1962). 
One percent molten agarose in normal saline containing 0.2% sodium azide was 
poured in on glass plate and allowed to solidify at room temperature. Required 
number of wells were cut and the slides were stored at 4°C. Fifteen to twenty 
microlitres of suitably diluted antisera and required amount of antigen prepared in 
normal saline were added in different wells. The reaction was allowed to proceed 
for 12-24h in a moist chamber at room temperature. The petriplates were 
immersed in normal saline to remove non-specific precipitin lines. 
Enzyme Linked Immunosorbent Assay (ELISA) 
Direct Binding ELISA 
Buffers and Substrate: Tris buffer saline (TBS), pH 7.4. 20mM tris, 150mM 
sodium chloride. Tris buffer saline Tween-20 (TBS-T), pH 7.4. 20mM tris, 
14.3mM sodium chloride, 200mg potassium chloride and 5ml Tween 20 was 
dissolved in 1 litre distilled water and pH adjusted to 7.4 with IN hydrochloric 
acid. Bicarbonate buffer, pH 9.5, 50mM containing 0.02% sodium azide as 
preservative. Substrate: 5mg p-nitrophenyl phosphate (in 10ml bicarbonate buffer). 
Procedure: Polystyrene microtitre plates were taken. The test wells were coated 
with lOO i^l of the antigen (Ilnd isoform, 0.5|ig/100ml of bicarbonate buffer). The 
plate was inoculated for 2h at room temperature and then overnight at 4°C. The 
plate was washed three times with TBS-T buffer. 
The unoccupied sites were saturated by incubation with 150ng/200|il of 1.5% 
milk in TBS for 5-6h at room temperature. Wash it twice with TBS-T. The test 
and control wells were then loaded with lOO i^l of serially diluted serum. Each 
dilution was in TBS buffer. Serially diluted blanks corresponding to each dilution 
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should be there. Then the plate was incubated for 2h at room temperature and 
overnight at 4°C. Wash five times with TBS-T buffer. Bound antibodies were 
assayed with an appropriate conjugate of anti-rabbit alkaline phosphatase (1:3000). 
100|il of it is coated in each well and kept for 2h at room temperature. Wash 
the plate with TBS-T five times and twice with distilled water. Add p-nitrophenyl 
phosphate (50|j,g/100|j,l) in each well and incubate at 37''C for 30-45min. The 
reaction was stopped by the addition of 100|il of 3M NaOH in each well. The 
absorbance of each well was monitored at 405nm on a Labsystems ELISA 
Reader. 
Inhibition ELISA 
The specificity of ELISA was ascertained by inhibition experiments (Ali and Ali, 
1986). Polystyrene microtitre plate was incubated with 100|il of the Ilnd isoform 
antigen (0.5|j.g/100|xl) for 2h at room temperature and then overnight at 4°C. The 
plate was washed three times with TBS-T buffer. 
Free sites were blocked by adding 150|xg/100|il of 1.5% milk in TBS buffer for 
6h at room temperature. Immune complex was made by adding varying amounts 
of the isoforms of inhibitor (.01-50|xg) with a constant amount of antibody (90^ig/ 
100(il). The mixture was incubated for 2h at room temperature. 100|il of the 
immune complex was coated and kept for 2h at room temperature then overnight 
at 4°C. Plate was washed with TBS-T four to five times. Then 100^1 of 
antirabbit conjugate alkaline phosphatase (1:9000 dilution) was coated to quantitate 
bound antibodies. The mixture was kept for 2h at room temperature. The plate 
was washed with TBS-T five times and twice with distilled water. Now add 
para-nitrophenyl phosphate (5mg/100|il) in each well and keep it for 30min at 
37"C. Stop the reaction by adding lOO/il 3N NaOH in each well. The absorbance 
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of each well was monitored at 405nm on a Labsystems ELISA reader. The 
results were expressed as percent inhibition 
inhibition 
% inhibition = xlOO 
uninhibited 
N-TERMINAL ANALYSIS 
Sequencing was performed on Shimadzu PPSQ-21 sequencer which employs 
Edman degradation to sequentially cleave and identify amino acids starting at the 
amino terminus (N-terminus) of the protein. The highly purified protein was 
transferred to the PVDF membrane before the analysis.. 
ANTIBACTERIAL ACTIVITY OF CYSTATIN 
The following bacterial reference strains were used: 
Siaphylococcus aureus 
Escherichia coli 
Streptococcus hemolyticus 
Bacillus subtilis 
Pseudomonas fluorescens 
Nutrient broth was composed of nutrient agar (1.3g/l). Ingredients of soft agar 
included agar agar (0.8g/100ml) and nutrient agar (1.3g/100ml) 
The antibacterial activity of cystatin isoform was checked by determination of 
inhibition zone diameter (Kasprzykowski, 2000). The bacterial strains were allowed 
to grow overnight in nutrient broth at 3TC, 0.3ml of the fresh culture were 
overlayed with soft agar on nutrient agar plates to aid the formation of the 
bacterial lawns. Whatman filter paper discs were put in 25ng/ml, 50|ag/ml, 100|ig/ 
50 
ml and Img/ml of inhibitor for the inhibitor to be absorbed on the discs. After 
2h the discs were placed careflilly on the bacterial lawn. The plates were then 
kept in the incubator at 37°C overnight. The antibacterial effect was classified as 
(+), +, ++ or +++ based upon the inhibition zone diameter of 11-12mm, 13-
14mm, 15-l^mm and 17mm and more than 17mm respectively. An absence of 
antibacterial activity is denoted by the symbol "—" in the table. 
SPECTRAL ANALYSIS 
UV Absorption Spectroscopy 
The UV absorption spectra of native and papain treated cystatin was taken by 
measuring the absorption between 200-3 50nm in a Camspec spectrophotometer in 
a cuvette of 1cm path length. Appropriate controls of the solvent buffer were 
taken. ISO i^g of the inhibitor in a total volume of 1ml was taken for the spectra. 
Fluorescence Spectroscopy 
Native and papain (activated with 20mM EDTA and 50mM cysteine) treated 
complex of cystatin were analyzed by measuring intrinsic florescence at 25±0.2°C 
in Hitachi F 2000 spectroflurometer (Tokyo, Japan). The protein was excited 
(Xex) at 280nm. Corrected emission spectra were recorded with excitation and 
emission band widths of lOnm. Controls containing the reagents used for the 
treatment were run and corrections made wherever necessary. 
To study the cumulative effect of tyrosine, tryptophan and phenylalanine, the 
protein was excited at 280nm. Denaturation of the inhibitor in the presence of 
8M urea, 6M GdnHCl and lOOmM (3-mercaptoethano! was studied. Solutions of 
1.2mM inhibitor with urea, GdnHCl and 3-mercaptoethanol with final 
concentration of 8M, 6M and lOOmM, respectively in 50mM sodium phosphate 
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buffer, pH 7.5, were mixed and incubated for 30 minutes. The temperature was 
maintained at 22"C by thermostating the cuvette housing during the measurement. 
The time of mixing was t=0. The fluorescence spectra were recorded after 30min. 
Circular Dichroism (CD) Spectroscopy 
Circular dichroism spectra of native cystatin and that after various treatments were 
measured in a Shimadzu spectropolarimeter equipped with a temperature controlled 
sample cell holder. Spectra were collected with a scan speed of 20nm/min and 
with a response time of Is. Measurements in the far UV (200-250 nm) were 
taken using 2.3 i^M (about 0.15 g/lit)cystatin, with a 1mm pathlength cells whereas 
cell with 1mm pathlength and cystatin concentrations of about 4.6nM (0.3 g/1) 
were used in the near UV (250-300 mm) region. For each sample, a solution of 
buffer or papain of the same concentration was used as a blank. 
The results were expressed as mean residue ellipticity (MRE) in deg. cm .^ dmol" 
' which is defined as 
MRE = 0^^ (m deg) / (10 x n x 1 x Cp) 
where 0^^ is the CD in millidegree, n is the number of amino acid residues, 1 is 
the pathlength of the cell and Cp is the mole fraction. The a-helical content of 
cystatin was calculated from the MRE value at 222nm using the following 
equation as described by Chen et al (1972) 
% helix =[(MRE,2,-2340)/30300] x 100 
The results in the near-UV CD were expressed as molar ellipticities. 
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KINETICS OF INHIBITION 
Stoichiometry of Proteinase Inhibition 
Papain was used for the titration of the two isoforms of cystatin. For this 
experiment activated papain (0.06|j,M) was incubated for lOmin at 37''C with 
increasing amounts of either isoform in 50mM sodium phosphate buffer, pH 7.5 
in a final volume of 1ml. 2ml volume of 2mM B -^Arg-p-NA was added to the 
mixture containing cystatin and this was incubated at 40''C for 60min. The 
reaction was stopped with 500|xl 0.3% (v/v) acetic acid and the liberated amine 
was assayed colorimetrically at 412 nm as described by Ganrot (1966). 
Identical experiments were carried out for the inhibitors with other proteinases 
also such as bromelain and ficin using casein as a substrate for bromelain and 
ficin described by Kunitz (1947) and Murachi and Neurath (1960). 
Ki Determination 
Ki determination were carried out according to the same procedure but after 
lowering enzyme and inhibitor concentrations to obtain a non-linearity of dose 
response curves. Thus papain was used at a concentration of 0.05|iM to react 
with I and II isoforms varying from 0.011 to 0.17|iM and measurement of 
residual activity were made as described by Kunitz(1947) using casein substrate. 
Four different substrate concentrations were used, i.e. 0.5Km, IKm, 2Km and 
3Km, with Km=2.4mM and the results were analyzed by the steady state 
equation of Krupka and Laidler (1959). This is linearized as follows (Henderson, 
1972). 
1-V/y, I Kmju, ^ ^' 0) 
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where [I]^, [E]^  and [S\ are the initial concentrations of inhibitor, enzyme and 
substrate,respectively. V^  is the velocity without inhibitor The plot of [iy(\-Y.fV^ 
against Vyv_ is a straight line, the slop of which gives 
K . c . p p ) = K i | u | ^ | (2) 
True Ki was obtained from a replot of Ki (app) against [Sj^ . 
Determination of Association Rate Constants (K j^) 
K ,^ values were determined by monitoring the time-dependence of the association 
under second-order conditions. Equimolar amounts of enzyme and inhibitor 
(O.OSjiM) in the final volume were mixed in a total volume of 1ml of the same 
buflfer, pH 7.5 at 37°C and residual activity was assayed as a fijnction of time 
after 0, 2, 5, 10, 15, 20, 25 and 30min as described above using casein as a 
substrate for papain, bromelain and ficin. 
Association rate constant (K ,^) was calculated assuming that enzyme (E) and 
either inhibitor (I) react according to eqn (3) and considering K, to be low 
enough to neglect the reverse reaction during the initial part of the process: 
E + I<»EI (3) 
Thus, when initial concentrations of enzyme, [E]^  and inhibitor [1]^  are identical, 
the integrated form of the equation giving association rate becomes: 
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where [I]^, [E]^  and [8]^ are the initial concentrations of inhibitor, enzyme and 
substrate,respectively. V^  is the velocity without inhibitor The plot of [I]g/(1-V./V^ 
against VyV^  is a straight line, the slop of which gives 
K , < « = K i | u | i | (2) 
True Ki was obtained from a replot of Ki (app) against [8] .^ 
Determination of Association Rate Constants (K ,^) 
K ,^ values were determined by monitoring the time-dependence of the association 
under second-order conditions. Equimolar amounts of enzyme and inhibitor 
(O.OSfiM) in the final volume were mixed in a total volume of 1ml of the same 
buffer, pH 7.5 at 37°C and residual activity was assayed as a fianction of time 
after 0, 2, 5, 10, 15, 20, 25 and 30min as described above using casein as a 
substrate for papain, bromelain and ficin. 
Association rate constant (K^^ ) was calculated assuming that enzyme (E) and 
either inhibitor (I) react according to eqn (3) and considering K, to be low 
enough to neglect the reverse reaction during the initial part of the process: 
E + I o E I (3) 
^-1 
Thus, when initial concentrations of enzyme, [E\ and inhibitor [I]^ are identical, 
the integrated form of the equation giving association rate becomes: 
[EI = [ E ' , ] ' * " * ' ' C) 
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Determination of Dissociation Rate Constants (K,) 
Conditions for maximal association between the proteinase and either inhibitor 
were achieved before the reaction was shifted towards dissociation by adding 
either a^M which forms stable and enzymically active complexes with free 
enzymes or excess of substrate, which also binds all the free enzyme (Beith, 
1980). Substrate induced dissociation was monitored with identical enzyme 
inhibitor complexes incubated for 30min at 37°C. Excess substrate (6% casein) 
was added to the mixture for different time periods and then assayed for their 
enzymic activity. 
On the basis of eqn (3) the dissociation of EI complex obeys first order kinetics 
during the initial part of the reaction, i.e. when there is almost complete 
association. In this case the integrated form of the dissociation rate equation is 
given by 
In-H.UK,t ^ '•- I rs) 
\n> ^-^ • 
From which K, and half-life of complexes may be calculated by rearranging as 
follows: 
to.3 - 0-693/K, 
Similar experiments for Ki determination, association and dissociation rate 
constants for ficin and bromelain were carried out with either inhibitor using their 
respective substrates. 
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CYSTATIN DAMAGE BY RIBOFLAVIN 
Cystatin damage and degradation by reactive oxygen species (ROS) was studied 
by riboflavin. Riboflavin was taken as a source of ROS on photoillumination. 
Time and Concentration Dependent Effect of Riboflavin on Cystatin 
1.76nM cystatin was incubated with SO i^M, lOO^M, 200^M, 300)iM and 400nM 
concentration of riboflavin in lOmM sodium phosphate buffer, pH 7.5 in a final 
volume of 500|il for 2h.Fixed molar concentrations of riboflavin and cyatatin 
were incubated for different time periods upto 5h in lOmM sodium phosphate 
buffer, pH 7.5. Incubation at room temperature (28-30°C) was performed under 
illumination of 500 flux from a fluorescent lamp. The reaction was stopped by 
adding the sample dye for PAGE. Aliquots of lOOfil were loaded on a PAGE for 
analysis. 
In another experiment the antiproteolytic activity of 1.76nM and 2.92|iM cystatin 
was analysed by incubating with lOOuM riboflavin for 60min. The activity was 
checked by taking lOOfil aliquots after 5, 10, 20, 25, 30, 35, 40, 45, 50 and 
60min respectively as described by Kunitz (1947). 
Effect of Copper (II) on the Activity of Cystatin 
The effect of Cu (II) in a final concentration of 100|iM was studied by 
incubation with photoilluminated riboflavin and cystatin in the final volume of 
300|il. Small aliquots from the reaction were taken for running PAGE (10%). 
Effect of Free Radical Scavengers 
To check the type of reactive oxygen species involved in the oxidation of cystatin 
scavengers of free radicals were used along with riboflavin. 25mM thiourea. 
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sodium formate, sodium azide, mannitol were used and incubated at room 
temperature under aerobic conditions. Retention of cystatin band in 10% PAGE in 
the presence of riboflavin showed the type of free radical involved in the 
reaction. 
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Results 
4. RESULTS 
I. ISOLATION AND PURIFICATION OF GOAT KIDNEY CYSTATIN 
The purification of cystatin in the present study was done by the modification of 
the method of Bige et al (1985). It involves alkaline treatment, ammonium 
sulphate fractionation, size exclusion chromatography and ion-exchange 
chromatography. The proteins obtained after alkaline treatment of the kidney 
homogenate were precipitated between 50-80% ammonium sulphate saturation. The 
precipitated proteins were dissolved in 50niM sodium phosphate buffer, pH 7.5 
and dialysed against the same buffer. This resulted in 7.63 fold purification and 
81% yield respectively. 
Gel Filtration 
Figure 4.1 shows the elution profile of the protein after dialysis on a column of 
Sephadex G-75 (2x55cm), equilibrated with 50mM sodium phosphate buffer, pH 
7.5 containing 0.15M sodium chloride. The thiol inhibitory activity was identified 
in the single protein peak which was followed by a minor inhibitory peak with 
insignificant protein content. The major peak had 61.1 fold purification and 71.6% 
yield after gel filtration. The minor inhibitory peak with very low protein content 
was not taken into consideration for fiirther studies. 
Homogeniety 
Homogeniety of the major protein inhibitory peak obtained from gel filtration 
column was determined by polyacrylamide gel electrophoresis in the absence of 
SDS. The pooled fractions of the major peak migrated as two bands in the gel 
indicating a charge heterogeneity (Fig. 4.2). 
Ion-Exchange Chromatography 
The major peak obtained from Sephadex G-75 column was further fractionated by 
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Figure 4.1 Gel filtration chromatography 
The ammonium sulphate precipitate obtained was dissolved and 
dialysed against several changes of 0.05M sodium phosphate buffer, 
pH 7.5 at 4°C. The fraction was applied on Sephadex G-75 (2 x 
55cm) and eluted with the buffer at the rate of 30ml/h. Fractions 
of 5.0ml were collected and assayed for inhibitory activity against 
papain and protein concentration. 
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Figure 4.2 Gel electrophoresis of goat kidney cystatin during various 
stages of purification 
Electrophoresis was performed on 10% non-denaturing gel as 
described under methods. Lane a contained kidney homogenate, 
lane b contained homogenate after alkaline treatment, lane c; 
dialysed fraction after ammonium sulphate fractionation, lane d; 
fraction after gel filtration and lane e and f contained the purified 
isoform I and II after ion-exchange chromotography, respectively. 
fiO 
a b c d e 
subjecting the pooled fractions to ion-exchange chromatography on DEAE-
cellulose column at pH 8.5. The protein was eluted by running a salt gradient 
(sodium chloride) of 0-0.3M (Fig. 4.3). Two protein peaks different on the basis 
of charge were obtained having cystatin activity. The fractions migrated as single 
band in non-denaturing polyacrylamide gel suggesting the homogeniety of the 
isolated protein in peak I and II (Fig. 4.2). The three step procedure resulted in 
266.5 and 229 fold enrichment in specific activity and a yield of 60.8 and 40.1%, 
respectively for peak I and II. The purification of cystatin has been summarised 
in Table 4.1. 
Homogeniety 
Homogeniety of the major protein inhibitory peak obtained from gel filtration 
column was determined by polyacrylamide gel electrophoresis in the absence of 
SDS. The pooled fi-actions of the major peak migrated as two bands in the gel 
indicating a charge heterogeneity (Fig. 4.2.). 
Reducing and Non-Reducing SDS PAGE 
Goat cystatin peak I and II isolated by ion exchange chromatography were 
analysed by SDS PAGE both under non-reducing and reducing conditions (P-
mercaptoethanol). A single band was obtained in the presence (Fig. 4.4A) and 
absence of P-mercaptoethanol (Fig. 4.4B) indicating the presence of a single 
polypeptide chain. However, under reducing conditions slight shifting of the 
protein bands was observed possibly due to oligomerization of the polypeptide 
chains. 
The SDS PAGE of the purified cystatin in the presence of 8M urea under 
reducing as well as non-reducing conditions (Fig. 4.5A and B) respectively did 
not result in any major change in the position of bands as the two proteins 
Figure 4.3 Ion-exchange chromatography 
Inhibitor obtained in major peak from gel filtration was fiarther 
purified by ion-exchange chromatography on DEAE-cellulose 
column (2.1 x 7cm) equilibrated at pH 8.5 by 0.05M phosphate 
buffer. The elution was performed in S.Omi fractions using a linear 
gradient of 0.0M-0.3M sodium chloride at a flow rate of 37ml/hr. 
Each fraction was assayed for thiol proteinase inhibitory activity 
(using casein as a substrate) and protein concentration. 
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Figure 4.4 SDS Polyacrylamide gel electrophoresis of tiie purified isoforms 
of goat kidney cystatin 
Electrophoresis was performed on 10% acrylamide gel as described 
under methods. (A) SDS PAGE of the purified cystatin under 
reducing conditions. (B) SDS PAGE of the purified inhibitor under 
non-reducing conditions. Lanes a and b contained 20|ig of I and II 
isoform, respectively. 
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Figure 4.5 SDS PAGE of the purified goat cystatin in the presence of 8M 
urea 
SDS PAGE was performed on 10% acrylamide gel as described 
under methods. (A) SDS PAGE of the cystatin isoforms in the 
presence of 8M urea under reducing conditions. (B) SDS-PAGE in 
8M urea under non-reducing conditions. Lanes a and b contained 
isoforms I and II respectively. 
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exhibited a single band in SDS PAGE. However, a similar slight oligomerisation 
was also observed with urea in the presence of P-mercaptoethanol, confirming 
that the effect was due to 3-mercaptoethanol only. 
PROPERTIES OF PURIFIED GOAT KIDNEY CYSTATIN 
Molecular Weight 
The molecular weight of goat kidney cystatin was determined under native as 
well as denaturing conditions. The molecular weight of cystatin under denaturing 
conditions was calculated from its mobility in SDS PAGE by the procedure of 
Weber and Osbom (1969). The mobilities of marker proteins were plotted against 
the logarithm of their molecular weights (Fig. 4.6). The least square analysis of 
the data indicated a linear relationship between log M and relative mobility (Rm). 
The position of migration of two forms of cystatin corresponded to 67 KDa (Fig. 
4.6). 
The molecular weight of the native cystatin was determined using gel filtration 
chromatography on Sephadex G-75. The marker proteins bovine serum albumin, 
ovalbumin, cytochrome C, ribonuclease were chromatographed on a column of 
Sephadex G-lOO (2x70cm) equilibrated with 50mM sodium phosphate buffer, pH 
7.5 and their elution volume determined. Analysis of data indicated linear 
relationship between log M and Ve/Vo, by Andrews (1964) method (Fig. 4.7) 
where Ve is the elution volume of a protein and Vo is the void volume of the 
column.The Ve/Vo of native cystatin corresponded to apparent molecular weight 
of 66 KDa, (Fig. 4.7). 
These results suggest that the two peaks I and II are isoforms. 
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Figure 4.6 Molecular weight determination of goat cystatin by SDS 
PAGE. 
Electrophoresis was performed on 10% acrylamide gel. The gel 
lane c contained the molecular mass standards: 1-phosphorylase b 
(97.4 KDa), 2-bovine serum albumin (68 KDa), 3-ovalbumin (45 
KDa), 4-carbonic anhydrase (29.1 KDa), 5-STI (20 KDa), 6-
lysozyme (14.3 KDa). Lane a and b contained 15|ig of |3-
mercaptoethanol treated isoforms I and II respectively, (Panel A). 
The relative mobility (Rm) of the marker proteins were plotted 
against their molecular weight using least square analysis. Identical 
Mr of the two isoforms is indicated by a single arrow. 
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Figure 4.7 Molecular weight estimation of purifled goat cystatin using 
Sephadex G-75 gel flitration chromatography. 
Purified goat cystatin was applied on a column of Sephadex G-75 
(2x70cm) and eluted with 0.05M sodium phosphate buffer, pH 7.5 
at a flow rate of 30nil/h. The molecular weight markers used were 
phosphorylase b (97.4KDa, Ph), bovine serum albumin (68KDa, 
BSA), ovalbumin (45KDa, Ova), chymotrypsin (26KDa, Chy), 
ribonuclease (12.7KDa, Ribo). The position of the elution of 
cystatin is indicated with an arrow. 
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Stoke's Radius 
As elution behaviour of a protein from gel filtration column correlates well with 
its stokes radius, the stokes radius of goat kidney cystatin was determined by its 
elution volume from a calibrated Sephadex G-75 column (2x70cm) using 50mM 
sodium phosphate buffer, pH 7.5 containing 0.15M NaCl using marker proteins 
(Fig. 4.8). The column was calibrated by determining the elution volume of 
several globular proteins with known stokes radii such as bovine serum albumin 
(35.5A), ovalbumin (27.3A), STI (22.4A), ribonuclease (19.2A) and cytochrome C 
(16.4A). The data was analysed according to the theoretical treatment of Laurent 
and Killander (1964) equation 
Kav= Ve-Vom-Vo 
V = elution volume, V void volume and V, = total volume. The linear plot 
e ' o = t r 
between stoke's radius and [-log Kav]"^ of the marker proteins was used for the 
calculation of stokes radius of cystatin (isoforms I and II) which was found to be 
35.3A for both isoforms. 
DifTusion Coefficient 
The difldision coefficient, D, of the inhibitor corresponding to this value of the 
stokes radius was computed to be 6.02x10"^  cm7s with the help of the equation 
D=KT/67iTir 
where K is the Boltzman constant (1.386x10'* erg/deg), T is the absolute 
temperature (303k) and T| is the coefficient of viscosity of the medium (O.OIOOP 
for water and dilute aqueous salt solutions at 20'^ ) (Friefelder, 1982). 
Carbohydrate Composition 
Type II cystatins are known to be devoid of carbohydrate content. However, goat 
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Figure 4.8 Determination of Stoke's radius of the purified cystatin by 
Laurent and Killander plot. 
The purified cystatin was subjected to gel filtration on Sephadex 
G-75. The K^ values were computed from the elution volume of 
marker proteins. Stokes radii for the marker proteins were bovine 
serum albumin (BSA, 35.sA), ovalbumin (Ova, 27.3A), ribonuclease 
(Ribo, I9.2A), cytochrome-C (Cyt, I6.4A). The stokes radius of 
both isoforms is indicated by a single arrow. 
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kidney cystatin isoforms I and II exhibited very low glycosylation of 2.8% and 
1.92%, respectively. 
Sulphydryl Groups 
No free sulphydryl groups were detected in the two isoforms of the purified 
cystatin in the native and denatured forms. 
Effect of Non-Specfic Proteolytic Enzymes 
The effect of proteolytic enzymes on native cystatin isoforms was analysed by 
treatment with trypsin, chymotrypsin and pepsin for 30min at 37°C (Fig. 4.9). 
Similar effect was observed in both isoforms. Trypsin did not cleave the inhibitor. 
However, chymotrypsin treatment led to the release of two fragments of 66KDa 
and 60KDa molecular weight, respectively. Cleavage by pepsin led to the release 
of a minor fragment in both the isoforms. 
Effect of Temperature 
The effect of exposure to temperature between 25°C-95°C is shown in Fig 4.10. 
Insignificant difference in the temperature labilities between the inhibitors was 
observed. Both the isoforms showed remarkable stability to a wide range of 
temperatures. 
Influence of pH 
The pH dependence of thiol proteinase inhibitors was analysed between pH 3.0-
9.0. Fig.4.11 shows that the isoform I is stable between the pH range 5.0-9.0 
and isoform II showed inhibitory activity from pH 4.0 to 9.0. 
Thermal Denaturation 
The two isoforms were exposed to 90°C for 2h. Isoform I retained inhibitory 
activity for 90min but lost 15% activity till 2h. However, isoform II showed 
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Figure 4.9 Effect of proteolytic enzymes on the purifled cystatin isoforms 
SOjAg purified isoforms I and II, were digested with l^ ig (1:50) 
proteolytic enzymes (trypsin, chymotrypsin and pepsin) respectively 
for 30min at ST^Cat pH 7.5, 7 and 4, respectively. The treated 
inhibitor was then subjected to 10% SDS-PAGE. Lane a: molecular 
weight markers, lane b: isoform I + trypsin, lane c and d isoform 
I with chymotrypsin and pepsin, respectively. Lane e, f and g 
contained isoform II with trypsin, chymotrypsin and pepsin, 
respectively. 
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Figure 4.10 EfTect of temperature on thiol proteinase inhibitor 
50|ig of thiol proteinase inhibitor isoforms I and II in 0.05M 
sodium phosphate buffer, pH 7.5, were incubated at various 
temperatures for 30min and then rapidly cooled. 30|ig of activated 
papain was added and kept for 60min at SVC and then the 
remaining procedure was the same as described in 'Methods' for 
inhibition assay using casein as substrate. The inhibitory activity of 
the inhibitor at 37°C was taken as 100%. (—) isoform I and (~) 
denotes isoform II. 
50 60 70 
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Figure 4.11 EfTect of pH on purified cystatin isoforms 
SOfig of the two isoforms were incubated with 0.05M sodium 
acetate buffer pH 3.0-6.0, phosphate buflFer pH 7.0-8.0 and tris-
HCl buffer pH 9.0 for 30min at S^C. After the incubation, the 
pH of the mixtures was neutralized and then 30jig of activated 
papain was added and the mixture was further incubated for 60min 
at 37°C. The following procedure was some as described in 
'Methods' using casein as substrate. The activity of papain in the 
absence of inhibitor at pH 7.5 was taken as 100%. (—) denotes 
isoform I and (~) isoform II. 
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lesser stability to high temperature and lost about 30% inhibitory activity (Fig. 
4.12). 
IMMUNOGENIC PROPERTIES 
Antibody Titre 
The high immunogenicity of the cystatin (isoform II) led to a high titre of the 
antibody in the serum of the rabbits. The titre of the antisera was determined by 
direct binding ELISA and found to be 19054.61 (Fig. 4.13). 
Cross Reactivity 
Goat kidney cystatin was highly immunogenic and readily induced antibody 
formation in rabbits. Fig. 4.14 shows that antisera raised against purified isoform 
II of cystatin cross reacted with the isoform I as indicated by a single precipitin 
line in immunodiffusion exhibiting total immunogenic identity between the two 
isoforms and homogeniety of the preparation. 
Cystatin also exhibited immunogenic identity with sheep plasma LMW kininogen 
as shown by a single precipitin line between the antibody and sheep LMW 
kininogen Fig. 4.15. 
Inhibition ELISA 
Because of high sensitivity, inhibition ELISA was adopted for the detection of 
immunological cross reactivity with the antibody raised against isoform II. 
Immunized sera showed a strong positive reaction in ELISA with isoform II with 
94% inhibition and about 75% inhibition with isoform I, Fig. 4.16. 
N-TERMINAL ANALYSIS 
Fifteen amino acids on the N-terminal of the two isoforms were detected by 
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Figure 4.12 Thermal denaturation of cystatin isoforms 
50ng of both the isoforms were incubated at 90°C for different 
time intervals in 50mM sodium phosphate buffer pH 7.5 and then 
rapidly cooled. 30)ig papain in activating agent was added and 
incubated for 60min at ST^ C and rest of the procedure for the 
activity was same as described earlier (—) indicates isoform I and 
(~) indicates isoform II. 
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Figure 4.13 Direct binding EUSA 
Serially diluted antisemm and pre immune serum were incubated 
with 0.5|ig/100|il antigen (isoform II). The procedure has been 
described in 'methods'. -©- denotes preimmunized serum and --•--
immunized serum. 
'^^-^^5"(5'5'f^^; 
• , •< il: I • I , -
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Figure 4.14 Ouchterlony immunodiffusion 
Antigoat cystatin isoform II antiserum was raised in albino rabbits. 
In the immunodiffijsion, cystatin antisera was allowed to react with 
the isoform I (40ng and 60 i^g) and isoform II. The central well 
contained the cystatin isoform II antiserum and well 1 and 2 
contained 40^g and 60|ig isoform I and well 3 contained 20iig 
isoform II cystatin. 
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Figure 4.15 Immunodiffusion of goat cystatin with sheep LMW kininogen 
Antigoat cystatin antisemm was allowed to react with sheep plasma 
LMW kininogen. The central well contained antigoat cystatin 
antiserum and well 1, 2 and 3 contained sheep plasma LMW 
kininogen, respectively. 
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Figure 4.16 Inhibition ELISA of isoforms I and n 
0.01-50|ig/0.1ml of isoforms I and II were incubated with 90|ig/ 
0.1ml of isoform II antiserum. Rest of the procedure is described 
in 'Methods' -•- denotes II isoform and ~o~ denotes isoform I. 
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automated Edman degradation method. Fig. 4.17 shows the amino terminal amino 
acid sequence of the purified cystatin. The two isoforms exhibited identical N-
terminal amino acid sequence. 
ANTffiACTERIAL ACTIVITY 
The results of cystatin subjected to different bacterial strains to study their 
biological effect have been summarised in Table 4.2. As is evident from the table, 
the growth of Stcphylococats aureus was inhibited to a greater extent by cystatin 
than other strains namely Escherichia coli., Streptococats hemolyticus, BaciUus 
subtilis and Pseudomonas fluorescens However, at 25|ig, 50|ig and lOOng/ml 
concentrations the inhibition was not significant. With a dose of Img/ml there was 
a considerable increase in the zone of inhibition (15-16mm). Moreover, cystatin 
was also able to inhibit the growth of Exoli to a greater extent as compared to 
S. aureus. At 100|ig/ml concentration of the inhibitor the zone of inhibition was 
about 16mm. S. hemolyticus resuUed in greater sensitivity to cystatin as at lOOpig/ 
ml maximum zone diameter of 17mm was observed. Inhibition of B. subtilis 
growth was found to be insignificant as it did not exhibit any increase in the 
inhibition zone diameter even at higher concentration of cystatin. Interestingly, 
Pseudomonas fluorescens was insensitive to cystatin as no zone of inhibition was 
observed. The sensitivity of bacterial strains with cystatin could therefore be 
sequenced as: 
S. hemolyticus > E.coli > S. aureus > B. subtilis > P. fluorescens 
11. SPECTRAL ANALYSIS 
Secondary and tertiary structural studies of the purified cystatin isoforms were 
performed by their uUraviolet (UV) absorption spectra, flourescence emission 
spectra and circular dichroism spectra in the near and far ultraviolet region. 
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Figure 4.17 N-terminal amino acid sequence of goat cystatin 
The highly purified cystatin was transferred to PVDF membrane by 
western blotting and then subjected to amino acid analyser for N-
terminal sequence. Homology with other known cystatin N-terminal 
sequences has been given in the boxes. 
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Goat c y s t a t i n 
Human aiKininogen: 
Bovine a2 kininogen: 
Beef a2 Kininogen: 
Human Cystatin S7: 
Human Cystatin S I : 
Cystatin S: 
Chicken Egg White 
(form I): 
Homology 
Cystatin C: 
Cystatin D: 
Cystatin E: 
Cystatin A: 
Cystatin B: 
D T H 1 S E K/Y 1 1 D C N D 1 G . 
E - S Q S E E J I D C N D K D 
E - SSQ- E- l l D C N D P Q Q 
Q E S - S Q ^ I D C N D | Q D V 
E N R0I P G G|T]Y D A[D| 
E - |T|l P G G[J]Y N A[D] 
S S S K ^EJN R| 1 1 |P G G[T]Y 
S E D R [ S ] R L L G A P V P V D 
S S P G K P P R L V G G P M D 
A Q S R T L A G G I H A 
R P Q E R M V G E L R D 
M I P G G L S E A K 
M M C G A P S A T Q 
15 
333% Homology 
333% Homology 
333% Homology 
20% Homology 
20% Homology 
26.6% Homology 
6.6% Homology 
0% Homology 
0% Homology 
0% Homology 
0%Homology 
0% Homology 
TABLE 4.2: ANTIBACTERIAL EFFECTS OF GOAT CYSTATIN 
Bacterial / Inhibitor 
Strain Cone. 
S. aureus 
E. coli 
S.hemolyticus 
B. subtilis 
P. fluorescence 
25ng/ml 
(+) 
+ 
(+) 
(+) 
-
50pig/ml 
(+) 
+ 
++ 
(+) 
-
lOO^g/ml 
+ 
++ 
+++ 
+ 
-
Img/mi 
-H-
++ 
+++ 
+ 
-
Inhibition zone diameter: - = no zone; (+) = 11-12 mm; + = 13-14mm; 
15-16mm; +++ = 17 or >17 mm. 
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UV Spectra of native and papain complexed isoforms 
The ultraviolet absorption spectra of the isoforms I and II were measured in 
50mM sodium phosphate buffer, pH 7.5 in the wavelength region 240-300 nm. 
The cystatin isoforms I and II absorbed maximally at 280nm as shown in Figs 
4.18. However, isoform II exhibited more absorbance at 280nm than isoform I 
(Fig. 4.18). The complex of papain and isoform I showed a marked increase in 
the absorbance with a concomittant disappearance of the peak at 280nm (Fig. 
4.19A). Similar effect was also observed in the complex of papain and cystatin 
isoform II (Fig. 4.19B). 
UV Difference Spectra of the Urea and GdnHQ Denatured isoforms I and n 
Denaturation of isoform I in the presence of 8M urea and 6M GdnHCl resulted 
in the marked increase in absorption due to the unfolding of native structure of 
the isoform. However, GdnHCl treatment led to a peak at 295nm whereas urea 
denaturation gave peak at 275nm (Fig. 4.20A). However, urea denaturation 
exhibited a 5nm blue shift. 
When isoform II was denatured by treatment with 8M urea and 6M GdnHCl, 
urea led to a marked increase in the absorbance. Fig. 4.20B. hence greater 
unfolding. However, GdnHCl denaturation could not lead to any significant peak 
in the absorbance. 
Fluorescence Spectra of Native and Papain Complexed Isoforms I and II 
The fluorescence emission spectra obtained for cystatin isoform I and II gave 
emission maximum at 351nm and 357nm (Fig. 4.21), respectively when excited at 
280nm. 
The complex of isoform I with equimolar papain caused a 5nm red shift of the 
emission maximum accompanied by a conformational change with a small 
84 
Figure 4.18 UV absorption spectra of native isoforms I and II 
l.SjoM isoform I and II in 0.05M sodium phosphate buffer pH 7.5 
were taken for spectra in the range 230-3 lOnm. Cells of 1cm 
pathlenght were used. (—•—) isoform I and (—O—) isoform II. 
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Figure 4.19 Ultraviolet absorption spectra of papain complex with I and II 
isoforms 
(A) The spectra of isoform I (—) and papain (—) (1.5|iM each in 
0.05M phosphate buffer, pH 7.5), and papain-isoform I complex 
( ). (B) The spectra of l.S i^M isoform II (—), an equimolar 
papain (—) and papain-isoform II complex ( ). The spectra was 
measured in the wavelength region of 240-3 lOnm. The complex of 
papain and inhibitor was incubated at 37°C for 30min. 
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Figure 4.20 Ultraviolet Difference spectra of isoform I and II under 
denaturing conditions. 
The spectra of 1.5|iM isoform I (A) and II (B) in the presence 
of 8M urea and 6M GdnHCl respectively was recorded in the 
range of 250-3 lOnm wavelength. The inhibitor was incubated with 
8M urea and 6M GdnHCl at 37°C for 30min before measuring 
the spectra.(—) with 8M urea and (—) with 6M GdnHCl. 
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Figure 4.21 Intrinsic fluorscence of native isoform I and II 
60^lg/ml of isoform I and II were taken in 50mM sodium 
phosphate buffer, pH 7.5. The inhibitors were exicited at 280nm 
(Xex) and emission was measured between 300-400 nm. The slit 
width was 10 nm for the exicitation and emission beam, 
respectively. Curve I denotes isoform I and II - isoform II. 
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enhancement in the fluorescence intensity (Fig. 4.22A). However, the complex of 
isoform II with equimolar papain did not cause any change in the fluorescence 
but a blue shifl of 6nm was observed (Fig. 4.22B). 
Effect of Denaturants on the Intrinsic Flourescence of Cystatin Isoforms 
I and 11 
Treatment of isoform I with 3M and 8M urea led to a slight decrease in the 
fluorescence intensity. Moreover, a red shift of 2nm and 9nm was observed with 
3M and 8M urea respectively (Fig.4.23A). Denaturation using GdnHCl led to a 
red shift of lOnm with 3M GdnHCl and a red shift of 16nm with 6M Gdn HCl 
and 28% decrease in the fluorescence intensity. The change in fluorescence with 
3M GdnHCl was negligible (Fig. 4.23B). 
3M urea treatment of isoform II exhibited a slight increase in the fluorescence 
without any change in the X,max. However, complete denaturation by 8M urea 
showed 15% decrease in the fluorescence and a red shift of 9nm (Fig. 4.24A). 
Treatment of isoform II with GdnHCl (3M) resulted in llnm red shift and a 
slight decrease in the fluorescence. However, denaturation with 6M GdnHCl 
resulted in further decrease in the fluorescence and a 15nm red shift, (Fig. 
4.24B). 
Denaturation under reducing conditions using 3-mercaptoethanol and 8M urea led 
to 40% decrease in the fluorescence with a 15nm red shift in isoform I due to 
complete denaturation and exposure of the hydrophobic groups, (Fig. 4.25A). 
Similar observation was obtained by denaturation of isoform II by 8M urea and 
P-mercaptoethanol (Fig. 4.25B). However treatment by P-mercaptoethanol only did 
not result in any significant change in fluoroscence intensity and X,max. 
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Figure 4.22 Intrinsic fluorescence of isoform I and II complex with papain 
(A) Fluorescence spectra of isoform I and papain-isoform I 
complex and (B) isoform II and papain-isoform II complex with 
an excitation wavelength of (Xex) 280nm and the emission between 
300 and 400nm was measured. Equimolar concentration of the 
inhibitor and papain was taken. The slit width was lOnm for the 
excitation and emission beam, respectively. The native inhibitor 
spectra is shown by — and papain complex by —. 
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Figure 4.23 Fluorescence spectra of isoform I on incubation with different 
concentrations of urea and GdnHCl 
(A) Isoform I (60ng/ml) (—) was incubated for 30min with 3M 
(—) and 8M urea (—) at 37°C. (B) 60^g/ml isoform I (—) was 
incubated with 3M (—) and 6M GdnHCl (—) for 30min at 370C. 
The extent of denaturation was measured after excitation at 280nm 
and emission spectra was taken between 300-400nm. The slit width 
was 10 nm for the excitation and emission beam, respectively. 
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Figure 4.24 Fluorescence spectra of isoform D after treatment with different 
concentrations of urea and GdnHCI 
(A) 60|ig/ml isoform II (—) was inclubated with 3M (—) and 8M 
(—) urea at 3TC for 30min. (B) Isoform II (60^g/ml) (—) was 
incubated with 3M (—) and 6M (—) GdnHCI for 30min at 37°C. 
The extent of denaturation was measured after excitation at 280nm 
and emission between 300-400nm. The slit width was lOnm for 
the excitation and emission beam, respectively. 
92 
A 
50.00 
0.0 ± -L 
300 320 340 360 
Wavelength (nm) 
380 400 
0.0 
300 320 340 360 
Wavelength (nm) 
380 4 00 
Figure 4.25 Fluorescence spectra of isoform I and n after denaturation in 
reducing condition 
(A) 60|ig/ml isoform I ( ) was treated with 8M urea and 
p-mercaptoethanol (—) and P-mercaptoethanol only (—). (B) 
60|ig/ml isoform II ( ) was incubated with 8M urea and 
|3-mercaptoethanol (—) and P-mercaptoethanol (—) for 30min at 
37°C. The extent of denaturation was measured after excitation at 
280 nm and emission between 300-400 nm. The slit width was 10 
nm for the excitation and emission beam, respectively. 
93 
300 
B 
50.00 
320 340 360 
Wavelength (nm) 
380 4 00 
300 320 340 360 
Wavelength(nm) 
380 400 
Circular Dichroism Spectra of Native and Papain Complexed Isoforms I and 
11 in Far UV Region 
The spectra for the purified cystatin isoform I is characterized by the presence of 
a minima at 209nm with a shoulder around 217nm, and isoform II showing a 
slight difference in mean residue ellipticity (Fig. 4.26). The CD spectra of the 
inhibitors show a predominant helical structure (Table-4.3) and only 9% P-
structure and 33.5% random structure. 
Complex of isoform I with papain resulted in complete loss of the helical 
structures and positive ellipticity in the range 205-215nm (Fig. 4.27A). Isoform II 
complex with equimolar papain exhibited a slightly different pattern with a 
maximum at 210nm and a small shoulder at 213nm. The helical structure is lost 
but the accompanying conformational change is different from the secondary 
structure change in the isoform I papain complex (Fig. 4.27B). 
Denaturation of isoforms I and II by 8M urea and 6M GdnHCl resulted in 
complete loss of ordered structure. 100% random structure was observed in 
isoform I and II respectively. Fig. 4.28(A,B). 
Circular Dichroism Spectra in the Near-UV Region 
The circular dichroism spectra in the near UV region reflects the contribution of 
aromatic side chains, disulphide bonds and prosthetic groups (Kuwajima, 1989: 
Dryden and Weir, 1991). The near UV spectra was taken in the wavelength 
range 240-320 nm. Fig. 4.29 shows absence of any significant absorbance around 
280nm which shows the asymmetric environment of tyrosine. Other wavelengths 
also showed the lack of any ordered tertiary structure for both the isoforms. 
Major conformational change was observed in the complex with equimolar papain 
(Fig. 4.30A,B). Tertiary structure was absent in 6M GdnHCl and 8M urea treated 
isoforms 1 and II respectively. 
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Figure 4.26 Far-UV circular dichroism spectra of native purified isoforms I 
and II 
Native isoforms I and II (2.2^iM, respectively) were taken in 
sodium phosphate buffer (50mM, pH 7.5). Phosphate buffer of the 
same concentration as in the sample was included in the blank. 
Cells of Icm path length were used. The unit on the ordinate is 
mean residue ellipticity. The mean residue weight for cystatin was 
calculated to be 115. 
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TABLE 4.3: RELATIVE PERCENTAGE OF THE SECONDARY 
STRUCTURES PRESENT IN ISOFORMS I AND II 
Protein 
1. Native I isoform* 
2. Native II isoform* 
3. Isoform I-papain 
complex* 
4. Isoform Il-papain 
complex* 
5. LMW sheep 
Kininogen (isoform I)* 
6. LMW sheep Kininogen 
(II isoform)* 
7. LMW sheep Kininogen 
(III isoform)* 
8. HMW sheep 
Kininogen* 
9. Chicken egg-cystatin* 
a-heiix 
29.6% 
25.5% 
17% 
26.6% 
27.1% 
22.9% 
14.2% 
23.5% 
21% 
P-structure 
9% 
17% 
-
-
23.9% 
21.6% 
22.3% 
57% 
42% 
p-turn 
27.9% 
22.4% 
-
-
17.4% 
19.2% 
22.2% 
0.7% 
24% 
Random coil 
33.5% 
35.2% 
83% 
73% 
31.6% 
36.3% 
41.6% 
18.9% 
12% 
•This study 
•Other study performed in the same lab 
•Chou & Fasman (1979 a,b) 
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Figure 4.27 Far-UV circular dichorism spectra of papain complex with 
isoforms I and II 
(A) 2.2|iM native isoform I (curve I) and complex of equimolar 
papain-isoform I (curve II). (B) 2.2|iM isoform II (curve I) and 
complex of equimolar papain (curve II). The complex was obtained 
after incubation at 37°C for 30min in 50mM sodium phosphate 
buffer pH 7.5. Cells of 1 cm path length were used. The unit on 
the ordinate is mean residue ellipticity. The mean residue weight 
for cystatin was calculated to be 115. 
97 
I 
o 
E 
TO 
CM 
£ 
u 
6» 
0; 
n 
u 
X 
<n 
r 
o 
220 
Wavelength ( n m ) 
230 240 
B 
210 220 230 
Wavelength (n m) 
24 0 
Figure 4.28 Far UV circular dichroism spectra of urea and GdnHCl 
treated isoforms I and II 
2.2nM isoform I (A) and 11 (B) were incubated with 8M urea and 
6M GdnHCl, respectively for 30min at 37°C before recording the 
spectra. Cells of 1cm path length were used. The unit on the 
ordinate is mean residue ellipticity. The mean residue weight for 
cystatin was calculated to be 115. Curve I represents native 
isoforms I and II, Curve II represents urea treated isoforms and 
curve III denotes GdnHCl treated isoforms. 
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Figure 4.29 Near-UV circular dichroism spectra of native isoforms 
(—) isoform I; (—) isoform II. 4.4|iM concentration of both the 
isoforms was taken in cells with 1 cm path length. The unit on 
the ordinate is molar ellipticity. The mean residue weight for 
cystatin was taken as 115. 
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Figure 4.30 Circular dichroism spectra of the complex of 4.4^M purified 
isoforms I and II with papain 
(A) Isoform I (—) and complex with equimolar papain (—). 
(B) Isoform II (—) and complex with equimolar papain (—). The 
complex was obtained by incubation at ST^ C for 30min. Cells of 
1 cm path length were used. The unit on the ordinate is molar 
ellipticity. The mean residue weight for cystatin was calculated to 
be 115. 
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III. KINETICS OF INHIBITION 
Stoichiometry of Inhibition 
The stoichiometry of association of purified kidney cystatin with papain was 
determined by reacting a fixed concentration of inhibitor with increasing 
concentration of papain. Amidase activity of papain using BAPA as substrate was 
determined with isoforms I and II, respectively. A linear increase in the inhibition 
upto 100% was observed indicating a complete association between enzyme and 
inhibitor under these conditions. One mole of the inhibitor complexed with one 
mole of papain ie. 1:1 ratio was obtained. The value was similar to that reported 
for chicken cystatin C. Identical stoichiometric ratio was obtained with bromelain 
and ficin. 
Ki Determination 
Ki values have been determined after lowering the papain and inhibitor 
concentrations, which favour the dissociation of the complexes, and using the 
steady state equation derived by Krupka and Laidler (1959). 
[M .KiruI^l^.[E]. 
1-V,/V„ I, Km;v„ 
Fig. 4.31 shows that Ki(app) increases as a function of the substrate 
concentration for both inhibitors. The true Ki value may be obtained from a replot 
of Ki(app) against [S]. The Ki(app) value obtained from the plot with papain 
were 2.1x10'" for isoform I (Fig 4.31 A) and 3xlO-'"M for isoform II (Fig. 
4.3 IB). 
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Figure 4.31 Ki determination with papain 
Papain was used at a final concentration of O.OSuM with 
increasing amounts of isoforms I and II (0.011-0.168|aM) and 
measurements of residual activity were made as described in 
methods using casein substrate. Four different substrate 
concentrations were used, i.e. 0.5Km, IKm, 2Km and 3Km with 
Km = 2.88x10* M. For the sake of clarity only the results 
obtained for [S]= IKm for isoform I (A) and [S]=0.5Km for the 
II isoform (B) are shown. The inset shows the replot of 
experimental Ki (app) values versus [S]. Intercepts on the ordinate 
give the true Ki. 
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Fig. 4.32 depicts the Ki(app) value determination for both the isoforms using the 
enzyme ficin. The values thus obtained were 9xlO"'°M for isoform I and 5xlO"'°M 
for isoform II (Fig. 4.32A,B). However, the Ki values obtained with bromelain 
were 2.2x10"^ and l.TxlO'M for isoforms I and II respectively (Fig. 4.33A,B). 
The Ki(app) value is lowest for papain hence, highest affinity. 
ICjg Value 
ICjQ is the concentration of inhibitor at which 50% of the enzyme is inhibited. 
The ICjQ values obtained with various thiol proteinases have been summarised in 
Table-4.4. The values obtained for the three thiol proteinases are comparable 
indicating that the affinities of these proteinases are similar with papain (0.09|iM 
and 0.079piM) having maximum affinity for both the isoforms. Ficin has ICj^  value 
of 0.115|iM and 0.09nM for isoforms I and II respectively. Bromelain has 
0.113|xM and 0.125nM value of Ic^ ^ for isoforms I and II respectively. 
Association Rate Constant (K^,) 
Association rate constants (K ,^) were calculated for the three thiol proteinases 
assuming that the enzyme and either inhibitor react in such a way that 
dissociation rate is low enough to neglect the reverse reaction during the initial 
part of the reaction. The equation obtained was 
— = + K,,t 
[E] [EJ 
Data in Fig. 4.34(A,B) show the plots of I/[E] versus time with papain.The slope 
of the straight lines obtained gives (K ,^) which is l.SxlO's and S.SxlO'^ s for 
isoforms I and II respectively. 
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Figure 4.32 Ki value determination with ficin 
Ficin was used at a final concentration of 0.05|iM with increasing 
amounts of isoforms I and II (0.011-0.168|iM) and measurements 
of residual activity were made as described in methods using casein 
substrate. Four diflFerent substrate concentrations were used, i.e. 
0.5Km, IKm, 2Km and 3Km with Km = 2.88x10"* M. For the 
sake of clarity only the results obtained for [S]= 0.5Km for 
isoform I (A) and [S]=0.5Km for the II isoform (B) are shown. 
The inset shows the replot of experimental Ki (app) values versus 
[S]. Intercepts on the ordinate give the true Ki. 
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Figure 4.33 Ki determination with bromelain 
Bromelain was used at a final concentration of 0.05|xM with 
increasing amounts of isoforms I and II (0.011-0.168nM) and 
measurements of residual activity were made as described in 
methods using casein substrate. Three different substrate 
concentrations were used, i.e. O.SKm, IKm and 3Km with Km = 
2.88x10"* M. For the sake of clarity only the resuhs obtained for 
[S] = O.SKm for isoform I (A) and [S] = 3Km for the II isoform 
(B) are shown. The inset shows the replot of experimental Ki 
(app) values versus [S]. Intercepts on the ordinate give the true 
Ki. 
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TABLE 4.4: KINETIC CONSTANTS FOR THE INTERACTION OF 
CYSTATIN ISOFORMS. 
PAPAIN 
Isoform I 
Isoform II 
Ficm 
Isoform I 
Isoform II 
Ki(M) 
2.1x10-'° 
SxlO'" 
9x10'° 
SxlO'" 
BROMELAIN 
Isoform I 
Isoform II 
2.2x10' 
1.7x10-' 
K, ,(M's ' ) 
1.5x10' 
8.6x10^ 
4.6x10^ 
5.3x10^ 
6.67x10^ 
2.5x10" 
K,(s-') 
6.14x10^ 
5.75x10-^ 
1.63x10-^  
2.3x10-^ 
5.37x10-" 
4.6x10^ 
Half life 
of complex 
1.13x10^ 
1.2x10^ 
4.25x10^ 
3.01x10^ 
1.3x10^ 
1.5x10' 
(HM) 
0.09 
0.079 
0.115 
0.099 
0.113 
0.125 
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Figure 4.34 Determination of association rate constants for papain 
Equimolar concentrations of papain and cystatin isoforms I and II 
(O.OSuM) were incubated and residual activity (Vi) was measured 
as a function of time for isoform I (A) and isoform II (B). The 
fractional activity ViA^ ^ is plotted against time. Insets represent a 
plot of the data in accordance with equation (4). 
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The association rate constants obtained for ficin with the cystatin isoforms are 
11.5x10^8 for isoform I and 6.67xl0^s for isoform II (Fig. 4.35A,B) For 
bromelain the association rate constant was computed to be lUxlO^s for isoform 
I and 13.8x10^8 for isoform II as depicted in Fig 4.36(A,B) 
Dissociation Rate Constants (K,) 
The conditions for the dissociation were taken as the enzyme-inhibitor complex 
obey first order kinetics during the initial part of the reaction. 
In this case the integrated form of the dissociation rate equation is given by 
llEIJoJ 
= K_,t 
log 
^[EI]^^-K_, t 
[EIJoj 2.303 
K, obtained with papain was 6.14x10"^ s' for isoform I and 5.75x10''s' for 
isoform II (Fig. 4.37A,B)- For ficin the Kj determination gave the value of 
1.63x10-^8-' and 2.303x10-^8-' for isoform I and II, respectively (Fig. 4.38A,B). 
The dissociation rate constant for bromelain was 5.37x10-^5' and 4.606x10^ s' for 
isoforms I and II, respectively (Fig. 4.39A,B). K, value is lowest for bromelain 
this result is in accordance with the highest K ,^ (for bromelain). The kinetic 
parameters of the isoforms with papain, ficin and bromelain have been summarised 
in Table-4.4. 
Half Life of the Complex 
Half life of the complexes may be calculated by re-arranging the equation 
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Figure 4.35 Association rate constant determination for ficin 
Equimolar concentrations of ficin and cystatin isoforms I and II 
(O.OSuM) were incubated and residual activity (Vi) was measured 
as a function of time for isoform I (A) and isoform II (B). The 
fractional activity ViA^ ^ is plotted against time. Insets represent a 
plot of the data in accordance with equation (4). 
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Figure 4.36 Association rate constant determination for bromelain 
Equimolar concentrations of bromelain and cystatin isoforms I and 
II (O.OSjiM) were incubated and residual activity (Vi) was 
measured as a function of time for isoform I (A) and isoform II 
(B). The fractional activity ViA^ ^ is plotted against time. Insets 
represent a plot of the data in accordance with equation (4). 
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Figure 4.37 Determination of rate constants for dissociation with papain 
Papain-isoform I and papain-isoform II complexes (l|xM) were 
preincubated for 30min at 40°C before excess substrate was added 
to the mixture. Appearance of papain activity was recorded as a 
fiinction of time. Insets show plots of the data. Isoform I (A) and 
isoform II (B). 
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Figure 4.38 Determination of rate constants for dissociation with flcin 
Ficin-isoform I and ficin-isoform II complexes (IjiM) were 
preincubated for 30min at 40°C before excess substrate was added 
to the mixture. Appearance of papain activity was recorded as a 
function of time. Insets show plots of the data. Isoform I (A) and 
isoform II (B). 
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Figure 4.39 Determination of rate constants for dissociation with bromelain 
Bromelain-isoform I and bromelain-isoform II complexes (l^M) 
were preincubated for 30min at 40°C before excess substrate was 
added to the mixture. Appearance of papain activity was recorded 
as a function of time. Insets show plots of the data. Isoform I 
(A) and isoform II (B) 
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Bromelain cystatin complex has longest half life. 
IV. EFFECT OF RIBOFLAVIN ON CYSTATIN ISOFORMS 
Inhibitory Activity in the Presence of Riboflavin 
On exposure to visible light of riboflavin produces superoxide radical, singlet 
oxygen and the flavin radicals (Kumari et al., 1996). Following incubation of 
cystatin with riboflavin and light for different time intervals (upto 30min), cystatin 
isoforms exhibited a gradual increase in their activity and at 1.76^M (Fig. 4.40), 
concentration of the inhibitor. However, the activity was found to be enhanced at 
2.94piM inhibitor concentration for the same time interval before declining to zero. 
Conformational Studies of Cystatin with Riboflavin 
To determine the conformational and structural status of cystatin exposed to 
riboflavin in the presence of light, samples of cystatin treated with 50HM-400(JM 
riboflavin for 5h were subjected to PAGE analysis. Cystatin showed almost 
complete degradation and at higher concentration of riboflavin crosslinking of the 
inhibitor was also observed. Fig. 4.41 A. Considerable damage of treated cystatin 
was obtained at SO i^M concentration of riboflavin. 
Incubation of cystatin for different time intervals with 100|aM riboflavin resulted in 
degradation of the treated cystatin with complete degradation after 5hrs 
incubation, Fig. 4.4IB, suggesting that cystatin is susceptible to oxidation and 
degradation by ROS. 
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Figure 4.40 Effect of riboflavin on the activity of cystatin 
(—•—) activity profile with 1.76^iM and (—o~) with 2.94}iM 
cystatin with constant riboflavin concentration of lOOjxM in final 
volume of O.Sml. The incubation was in fluorescent light at 28°C 
for diflFerent time intervals. Anti caseinolytic activity of cystatin was 
checked against papain. 
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Figure 4.41 PAGE of cystatin damage by riboflavin 
(A) Cystatin (1.76)iM) was incubated in fluorescent light for 5h at 
28°C with diflferent concentrations of riboflavin in a final volume of 
0.5ml. Lane a: untreated cystain, lane b: cystatin + 50|xM 
riboflavin, lane c: cystatin + 100|iM riboflavin, lane d: cystatin + 
200|xM riboflavin, lane e: cystatin + 300|jM riboflavin and lane f: 
cystatin + 400nM riboflavin. (B) 1.76|iM cystatin and lOOfiM 
riboflavin in 0.5ml reaction volume were incubated at 28°C in 
fluorescent light for different time intervals. Lanes a,b,c,d,e,f & g 
represent cystatin alone and cystatin + riboflavin after 30min Ih, 
2h, 3h, 4h and 5h, respectively. 10|xg cystatin was run on 10% 
PAGE and stained with silver nitrate. 
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Effect of Cu (II) and Riboflavin on Cystatin 
Cystatin exhibited mild change in its activity in the presence of 100|iM Cu(II). 
However, a complete loss in inhibitory activity was detected in the presence of 
Cu(II) and photoilluminated riboflavin. Although, 40% activity of cystatin was 
observed with photoilluminated riboflavin only (Table 4.5). When this system 
(cystatin + Cu(II) + riboflavin) was kept in dark 26% activity was observed 
whereas riboflavin control (cystatin + riboflavin) exhibited more than 50% of the 
inhibitory activity in the dark. These results suggest that Cu(II) in itself is not 
interfering with cystatin, it is an activator in the production of free radicals by 
photoilluminated riboflavin. Fig. 4.42 shows the analysis of ROS involved. It was 
found that hydroxyl radicals were responsible for damage. 
Involvement of Oxygen Free Radicals in the Reaction 
It is well known that riboflavin generates superoxide radical, singlet oxygen and 
flavin radical. For this reason the effect of several free radical scavengers on 
cystatin damage was examined. Singlet oxygen is quenched by sodium azide, 
potassium iodide is a flavin triplet state scavenger (Dhal and Richardson, 1980), 
thiourea, sodium formate and mannitol eliminate hydroxyl radical (McLord and 
Fridovich, 1969; Joshi, 1985). As shown in fig. 4.42B, thiourea and potassium 
iodide strongly inhibited cystatin degradation and activity loss by riboflavin 
suggesting that flavin triplet state and hydroxyls radical are the possible ROS 
involved in the damage of inhibitor. The quenching effect of sodium azide was 
less pronounced suggesting that singlet oxygen may also be produced to some 
extent. 
Spectral Analysis of Riboflavin and Cystatin 
The conformational changes in cystatin due to riboflavin were also analysed by 
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TABLE 4.5: RESIDUAL ACTIVITY OF PURIFIED CYSTATIN IN THE 
PRESENCE OF Cu (H) AND RIBOFLAVIN 
Reaction conditions 
Cystatin + riboflavin (light) 
Cystatin + riboflavin (dark) 
Cystatin + Cu(II)+ riboflavin (dark) 
Cystatin + Cu(II)+ riboflavin (light) 
% Residual activity 
40 
57 
26 
0 
The concentration of riboflavin and Cu(II) used was lOOuM, respectively. Cystatin riboflavin 
system was incubated for Ih in the given reaction conditions and then the activity of cystatin 
was analysed by the method of Kunitz (1947). 
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Figure 4.42 PAGE of cystatin and riboflavin in the presence of free radical 
scavengers 
(A) PAGE of cystatin and riboflavin in the presence of Cu(n) after 
incubation with ROS scavengers. 1.76nM cystatin with lOOiiM 
riboflavin and 100|JM CU(II) was incubated with scavengers, 25 mM 
each in a final volume of O.Sml under fluorescent light at 28°C for 
Ih. The reaction was stopped by adding the sample dye of PAGE. 
Lane a: cystatin alone, lane b: cystatin + riboflavin + Cu(I), lane 
c, d,e and f represents cystatin, riboflavin Cu (II) with thiourea, 
potassium iodide, mannitol and sodium azide. (B) PAGE of cystatin 
with free radical scavengers. Lane a: cystatin, lane b: cystatin + 
riboflavin, lane c: cystatin, riboflavin + thiourea, lane d: cystatin, 
riboflavin and sodium formate, lane e: cystatin, riboflavin + 
potassium iodide, lane f,g: cystatin, riboflavin with mannitol and 
sodium azide, respectively. 
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UV absorption and fluorescence spectra. Fluorescence spectra of native and 
riboflavin exposed cystatin were measured, Fig 4.43A. Complete quenching of the 
fluorescence was obtained even at 50|iM riboflavin indicating a major 
conformational change. The quenching of fluorescence has been observed even 
after 5min of incubation in light. Fig 4.43B. However, after the removal of 
riboflavin cystatin exhibited marked increase in the fluorescence intensity, Fig 4.44. 
Cystatin regained about 50% of its activity after dialysing out riboflavin. Dialysis 
of treated cystatin upto 2h to remove riboflavin led to 40% regain in activity. 
After 4h dialysis 43% inhibitory activity of cystatin was regained. However, 
overnight dialysis of the same sample could led to the reversal of 49% inhibitory 
activity of cystatin. 
The UV absorption spectra of riboflavin with cystatin. Fig 4.45, shows a decrease 
in absorption at 440nm supporting the observations in fluorescence spectra. 
Generally, riboflavin gives a visible spectrum below 500nm with a minor peak at 
370nm and a major peak at 440nm. 
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Figure 4.43 Fluorescence spectra of cystatin after treatmentwith lOO^M 
riboflavin 
(A) The spectra of cystatin after treatment with different 
concentrations of riboflavin. ( ) the fluorescence spectrum of 
native cystatin and (—) and (—) are the fluorescence spectrum of 
cystatin after incubation with 50|xM and lOO^M riboflavin. (B) 
Fluorescence spectra of cystatin after different time incubation. 
(—) corresponds to fluorescence spectrum of native cystatin (—) 
and (—) correspond to cystatin treatment with riboflavin after 5min 
and lOmin. 
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Figure 4.44 Fluorescence spectra of cystatin alone (—) and riboflavin 
treated cystatin (—) and cystatin after removal of riboflavin 
( ) 
Riboflavin was removed by dialysis in 0.05M sodium phosphate 
buffer for 15h. 
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Figure 4.45 UV absorption spectra of riboflavin 
lOO i^M riboflavin (—•—) and riboflavin and 1.76fiM cystatin 
(...o--) after 30min incubation and (—A—) after 60min incubation. 
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5. DISCUSSION 
Endogenous thiol proteinase inhibitors constitute the ultimate level of regulation of 
the overall cellular activity of cysteine proteinases (Sotiropoulou et al., 1997). The 
unique properties and a wide range of physiological roles of CPI are indeed 
engrossing and attract remarkable attention. A proteinase inhibitor is of 
physiological importance because inhibition is achieved at physiological 
concentration of the inhibitor in a sufficiently short time with negligible 
dissociation of the complex (Beith, 1980). CPI have important regulatory role in 
normal body processes involving CP activity which otherwise may lead to 
excessive proteolysis and damage to tissues. Numerous pathological conditions 
have been connected to increased CP activity including septic shock (Assfalg-
Machleidt et al., 1988), cancer progression (Sloanne, 1990) as well as 
inflammatory reactions (Mort et al., 1984; Buttle et al., 1990; Cox and Eley, 
1989). Extensive work has been carried out for the purification and 
characterization of these inhibitors using various isolation procedures. Purification 
of CPI has been reported by various laboratories from a variety of mammalian 
organs such as muscle (Zabari et al., 1993), liver (Green et al., 1984), spleen 
(Jarvinen and Rinnie, 1982), salivary glands (Nishiura et al., 1991). The CPIs 
have been isolated in multiple forms from several organs. However, kidney being 
the key member of the physiological system was chosen for the present study as 
lacuna exist in the isolation and physico-chemical characterization of cystatin from 
this organ. Thus, it was envisaged that a thorough and systematic study of CPI 
from a new source that is kidney will be useful in understanding in-depth about 
cystatins of mammalian system and to compare its properties with other known 
cystatins. 
124 
The purification of kidney cystatin was achieved using a simple three step 
procedure which includes ammonium sulphate fractionation, gel fihration and ion 
exchange chromatography. Two purified proteins differing in their net charge were 
obtained. The procedure is simple and rapid with 60.8% and 40.1% recovery and 
266.5 and 229 fold enrichment in specific activity for each protein was obtained 
(Table 4.1) 
Purification of CPI from other sources have been reported using affinity 
chromatography and chromatofocusing, gel filtration and ion exchange 
chromatography(Anastasi et al., 1983; Evans and Barrett, 1987;Pontremoli,1983; 
Cimermann at al.,1996; Turk et al., 1983). Bige et al (1985) and Green et al 
(1983) have also isolated multiple forms of cystatin from bovine muscle and 
human liver, respectively. 
The Mr of the purified inhibitor by SDS-PAGE under reducing conditions was 
found to be 67KDa (Fig 4.6) which is slightly higher than the value obtained by 
gel filtration under native condition on Sephadex G-75 column which was 66KDa 
for both the inhibitor forms (Fig. 4.7). This discrepancy may be accounted for by 
the fact that kidney cystatin on denaturation under reducing conditions forms 
aggregates. This result is supported by the work of Ekiel et al (1997). 
When SDS PAGE was performed in non-reducing conditions single protein band 
was obtained at position corresponding to 66BCDa. These results suggest that the 
two proteins are single polypeptides. The homogeneity was also confirmed by the 
presence of single band in pore-size electrophoresis (Fig. 4.3). 
Cystatin type I (stefin) and type II have been classified on the basis of molecular 
weight and presence of disulphide bonds. As a resuU cystatins from tissues are 
usually small inhibitors having Mr in the range of 11 to 25KDa. CPI from bovine 
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brain has two molecular forms of 25 and llKDa (Aghajanyan et al., 1996), 
isoforms from bovine muscle has Mr of 14KDa and 14.3KDa (Zabari et al., 
1993), human liver cystatin has 14.2KDa (Green et al., 1984), human placental 
CPI has 12.3KDa Mr (Warwas and Sawicki, 1985), bovine stefin A has ll.lKDa 
and stefin B has 12KDa (Turk et al, 1995) and stefin C has Mr of 11.5KDa 
(Turk et al, 1993). 
Hence, the anomalous Mr of the cystatin obtained in the present study shows 
that this cystatin can not be placed in either type I or type II cystatins. 
Consequently, it can be referred to as a new class of cystatins which have higher 
molecular weight in tissues. 
Hydrodynamic parameters for the inhibitors as determined from gel filtration 
behaviour suggested a similar stokes radius of 35.3A for each inhibitor form (Fig. 
4.8) and diffusion coefficient of 6.02 x 10'^  cm7s. Diffusion coefficient depends 
upon size and shape of a molecule. The compact globular protein like BSA has 
diffusion coefficient of 6.7x10'^ cmVs and stokes radius of 37A (Ghosting, 
1956).The above finding indicates that both the isoforms posses a globular 
conformation under native condition comparable to BSA, The significant deviation 
from compact globular shape (Huisman et al., 1974) may be attributed to 
substantial glycosylation of the isoforms which is 1.8% and 2.9% for I and II 
forms of the inhibitor, respectively. Generally cystatin type I and type II which 
are isolated from tissues lack carbohydrate content (Barrett, 1984). It has been 
reported that rat cystatin C isolated from urine is slightly glycosylated (Bode et 
al., 1988; Esnard et al., 1988). Ni et al (1997) found carbohydrate attachments in 
cystatin E. Glycosylation has also been demonstrated in cystatin F and cystatin M 
(Ni et al., 1998 and Sotiropoulou et al., 1997). Presence of carbohydrate chains 
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is a distinguishing property of type HI cystatins, kininogens (Ryley, 1979; Salvesen 
et al., 1985; Gounaris et al., 1984). 
The above discussion leads us to the conclusion that the two isoforms of the 
inhibitor are identical on the basis of molecular weight, stokes radius and gel 
filtration behaviour but differ in their carbohydrate content. Both isoforms are 
devoid of free thiol groups characteristic similar to type I cystatins (Barrett, 
1984). This result is in agreement with the findings of Bige et al (1985) for 
bovine muscle. 
The isoforms are highly stable towards high temperature and pH range as 
reported for other cystatins (Figs 4.10,4.11,4.12). Zerovink et al (1997) have 
shown high thermal stability of chicken cystatin and stefins A and B. However, 
Barrett et al (1986) reported similar stability in inhibitory activity of LMW-CPI 
upto lOOT for 5 min. 
Excision of cystatin by trypsin, chymotrypsin and pepsin suggest that cystatin has 
a two domain structure (Fig. 4.9). No cleavage site for trypsin was detected but 
chymotrypsin and pepsin have single susceptible cleavage site which separates the 
cystatin into two domains. However, the heavy chain of LMW kininogen which is 
similar to cystatin has been shown to be cleaved into three domains (Salvesen et 
al., 1986). Trypsin cleaved the heavy chain into two domains. Proteolysis of the 
larger fragment by chymotrypsin further cleaved it into two domains. The 
proteolysis of kidney cystatin resembles the cleavage of the heavy chain of LMW 
kininogen by chymotrypsin although it is different from the cleavage reported by 
Salvesen et al (1986)indicating that the site of cleavage of this cystatin is different 
which further makes it a strong case for placing it in a new class. 
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Isoform I and II were found to be immunologically identical on imunodiffusion 
plate as they gave a single precipitin line with the antiserum against isoform II 
(Fig 4.14). The high titre of the antiserum obtained establishes that this inhibitor is 
highly immunogenic (Fig 4.13). Inhibition ELISA of the antibody raised against 
isoform II showed 84% inhibition of isoform I suggesting that the two isoform 
may be similar in their properties but they are not identical in structure and 
immunogenicity. The antisera also cross reacted with sheep LMW kininogen 
(Fig.4.15) indicating an immunological identity with kininogens, again a supporting 
evidence for the fact that its properties are in between cystatin type II and 
kininogens. 
N-terminal analysis of the cystatin isoforms resulted in the identical amino acid 
sequence of N-terminal 15 amino acid residues (Fig. 4.17). The sequence analysis 
suggests that the N-terminus is hydrophilic. This is incoherence with the 
observation that the cystatin have hydrophilic and flexible N-terminus (Dieckmann 
et al., 1993). Ironically no glycine at position 9, a residue important for the 
interaction of CPI with CP, was found instead it is present at position 15. In 
human cystatin C glycine is found at 11 rather than position 9 (Brzin et al., 
1984). Examination of the homology of the N-terminus of kidney cystatin with 
other cystatins in the available data base gave 33.3% sequence homology with 
human, bovine and beef LMW kininogens (Ohkubo et al., 1984; Nawa et al., 
1983) and 20% homology with the N-terminus of type II cystatins, human 
cystatin C, S7 and SI (Grubb and Loft)erg, 1982; Grubb et al., 1984; Isemura et 
al., 1984 a,b; 1986). No homology was found with other members of class II 
cystatin (Schwabe et al., 1984). 
It is evident from the above results that the cystatin from goat kidney cannot be 
placed in either class of cystatin superfamily. We therefore, propose it to be a 
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new cystatin, 'cystatin K' from goat kidney. The strong support for the 
uniqueness of this cystatin came from the molecular weight value, N-terminal 
sequence and immunological cross reactivity that this cystatin has properties in 
between type III kininogens and cystatin type II. However, it lacks disulphide 
bonds and is devoid of subunit structure which is a characteristic of type I and 
type II cystatins. Subunit structure is found in kininogens, type III cystatins 
(Salvesen et al, 1986). 
Cystatins are known to possess antimicrobial activity. Bjorck et al (1990) reported 
that the human cystatin C blocks herpes simplex virus replication and human 
corona viruses (Collins and Grubb, 1991). Poliovirus culture was inhibited when 
the medium was supplemented with chicken cystatin and human cystatin (Korant 
et al., 1985; 1986) especially parotid cystatin (Cimermann et al., 1996). Inhibitory 
effect of human cystatin C on various gram positive and gram negative bacterial 
strains was investigated by Kasprzykowski et al (2000). Antibacterial property of 
goat cystatins was analysed on five bacterial strains. The zone of inhibition 
obtained suggest that S. hemolyticus is most susceptible to cystatin inhibition and 
P. fluorescem being least eflfected (Table 4.2). However, this observation does not 
give any idea regarding the mode of action of these cystatin isoforms. 
Kasprzykowski et al (2000) have proved that the proteinase inhibitory capacity of 
compounds structurally related to the inhibitory centre of cystatin C is not 
required for their antibacterial activity. 
The UV absorption spectra of isoforms I and II is shown in Fig 4.18. The 
greater absorbance of isoform II can be attributed to a comparatively high content 
of aromatic amino acids as compared to isoform I. The spectra of the complex 
of isoforms with papain (Fig. 4.I9A,B) exhibited a high positive peak with a 
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blue shift. This conformational change in complex formation could be due to 
perturbation of tryptophan. 
Denaturation of isoform I using 8M urea and 6M GdnHCl causes the unfolding 
of the native structure as a result of which the UV absorption increases (Fig. 
4.20A,B)The positive peak in the difference spectra represents increased 
absorbance. GdnHCl brought about greater unfolding of isoform I. However, in 
case of isoform II any significant increase in the absorbance by GdnHCl was not 
observed indicating local interactions affecting chromophoric groups without 
involvement of conformational change instead urea led to a greater unfolding of 
the inhibitor without any change in the A,max. Thus, it can be concluded that 
denaturation by urea did not cause any major change in the polarity of the 
environment. 
The fluorescence emission spectra of the isoform I and 11 gave emission 
maximum at 351 and 357nm, respectively (Fig.4.21).The complex of isoform I 
with equimolar papain (Fig. 4.22) caused a 5nm red shift and an increase in 
fluorescence intensity suggesting that the conformational change has led to the 
exposure of absorbing groups to polar environment or tryptophan has come near 
the charged group (Friefelder, 1982). The increase is due to loss of compact 
structure. Further, isoform II complex with papain (Fig. 4.22B) resuhed in 6nm 
blue shift without any change in intensity which indicates that tryptophan residues 
are transferred to a more hydrophobic environment accompanying local 
interactions(Chen. et al, 1969; Donovan, 1973). Lindahl et al (1988) reported 
analogous blue shift and decrease in fluorescence for papain cystatin complex. 
Moreover, a larger decrease of the fluorescence intensity was observed by Takeda 
et al (1986). 
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The apparent red shift when isoform I was treated by 3M urea (Fig. 4.23A) was 
due to a conformational change leading to the movement of fluorophores to a 
polar environment which was further increased by 8M urea as the unfolding 
increased (Freifelder, 1982). GdnHCl denaturation also gave analogous results. 
However, the red shift was greater and the decrease in fluorescence observed was 
20% as compared to urea (Fig. 4.23B). The results of UV difference spectra are 
also consistent with the finding of fluorescence spectra. 
Reduction of isoform I and n in the presence of 8M urea and P-mercaptoethanol 
(Fig. 4.25B) led to drastic change in the polarity of the environment resulting in 
the decrease in fluorescence intensity with a red shift indicating an exposure of 
aromatic groups. The absence of disulphide bonds was fijrther supported by the 
fluorescence spectrum of the inhibitors with P-mercaptoethanol exhibiting no 
change in fluorescence intensity and Xmax. 
Circular dichroism (CD) is a convenient and widely used method for studying the 
conformational changes of globular proteins in solutions (Provencher and Glockner, 
1981). The a-helical structure of the protein in far UV CD is characterized by 
negative peaks at 208-2 lOnm and 222nm and a positive peak between 190-192nm 
(Jirgensons, 1970; Saxena and Wetlaufer, 1971; Chen et al., 1972). The far UV 
CD of the native isoforms (I and II) (Fig. 4.26) is devoid of a clearly outlined 
negative peak at 222nm, but a negative peak at 209nm is obtained. The presence 
of a shoulder instead of peak at 222nm is due to the contribution of the 
unordered structure which also absorbs at this wavelength (Chen et al., 1972) 
(Table 4.3). The amplitude of the absorbance is a measure of ordered 
conformation (Jirgensons, 1970) which shows that isoform II is less ordered than 
isoform I. This is also supported by the data in Table 4.3, which indicates that 
131 
the content of random stmcture in isoform II and isoform I are 35.2% and 
33.5% respectively. The CD pattern of these inhibitors closely resembles that of 
lysozyme which has 29% a-helix, 16% P and 55% random structure (Blake et 
al., 1965). Similarly, far UV CD spectra reported for chicken cystatin by Lindahl 
(1988) with a minimum at 208nm and a shoulder at 222nm. 
The complexes of isoform I and II with equimolar papain acquire a random 
structure as is evident from the Fig. 4.27(A,B). The fraction of helical structure is 
reduced to 17% for isoform I, however, isoform II complex has greater fraction 
of ordered structure 26% (Table 4.3). A typical unordered protein structure has 
small positive band at 218-219nm and a small negative band near 225 nm (Chen 
et al., 1972). This result does not agree with the data reported in the literature 
showing that cystatin complex with papain does not give a drastic change 
(Lindahl et al., 1988; Takeda et al., 1986). In the present study a major 
conformational change is depicted. 
CD results also show that the denatured isoforms (by 8M urea and 6M GdnHCl) 
were 100% random structures. Urea denatured isoforms displayed a negative band 
at 225nm, characteristic of random structure. However, GdnHCl denatured 
isoforms gave small negative peak at 215nm (Fig. 4.28A,B) suggesting that the 
mode of interaction of this cystatin with the two denaturants is different from 
urea. 
The near UV circular dichroism spectra of the native isoforms reflect negligible or 
very weak positive bands in the wavelength range of 250-320 nm (Fig.4.29). 
Weak bands in the near UV spectra are exhibited by the proteins which are 
devoid of disulphide bonds and have low content of the aromatic amino acids 
(Jirgensons, 1970). Low content of tryptophan is exhibited by weak positive band 
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near 280nm (Adler et al, 1973). The near UV CD results of the isolated 
inhibitor support the absence of disulphide bonds and that the inhibitors lack any 
ordered tertiary structures. Similar structure has been reported for chicken cystatin 
by Lindahl et al (1988). 
The complexes of isoform I and II with equimolar papain gave a clear picture 
of major conformational changes (Fig.4.30A,B) in which phenylalanine is exposed 
as evident from the negative band around 260nm. The ordered conformation was 
totally lost after denaturation by GdnHCl and urea. 
The above mentioned results give a detailed idea about the structure of kidney 
cystatins and we reach to a conclusion that 'cystatin K' has a predominant a-
helical structure with small percentage of P-structure. Complex of cystatin with 
equimolar papain gives a random structure where some a-helices are conserved. 
This cystatin has very low content of aromatic amino acids and lacks disulphide 
bonds without any defined tertiary structure. 
Stoichiometry of binding of the isoform I and II with papain, bromelmn and ficin 
was determined by titration of the proteases with the inhibitor. The thiol protease, 
inhibitor stoichiometry of 1:1 was obtained for bromelain, ficin and papain. This 
suggests that cystatin is a tight binding inhibitor for these proteases. Anastasi et 
al (1983) and Nicklin and Barrett (1984) reported equimolar complexes of 
cystatin with cysteine proteinases. The result is also consistent with the findings of 
Abrahamson et al (1987). However, the binding ratio of 1:2 has also been 
observed by Bjork et al (1989). 
The two isoforms are potent inhibitors of thiol proteinases is evident by their Ki 
values which was determined by Henderson's (1972) method. It was readily 
apparent that the degree of inhibition varied with absolute concentration of the 
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inhibitor as expected for tight binding reversible inhibition. The kidney cystatin 
exhibited a Ki of 2x10'° M and SxlO'" M for isoform I and II respectively for 
papain (Fig.4.31), 9x10'° M and 5x10'° for both isoforms with ficin (Fig.4.32) 
and Ki value of 2.2x10' M and 1.7 x 10' M with bromelain (Fig.4.33) as 
depicted in the Table 4.3. A comparison of Ki (app) values indicate that this 
cystatin has highest aflSnity for papain, then ficin and least with bromelain. It has 
been reported that cystatin isolated from other sources generally do not inhibit 
bromelain but in the present study bromelain is found to be inhibited. However, 
there is a report that shows bromelain is inhibited by human placental cystatin 
(Warwas and Sawicki, 1985) and human spleen CPI (Jarvinen and Rinnie, 1982). 
The values are in good comparison with other thiol proteinase inhibitors. The 
inhibition constant (Ki) for chicken cystatin and cystatin C is 5x10'^ M with 
papain. Ki values of nanomolar range have been predicted for cathepsin B, H and 
L (Cystatin A, Barrett et al., 1984a; Cystatin C, Machleidt et al., 1986; Chicken 
cystatin, Salvesen et al., 1985; Cystatin D, Balbin et al, 1994). The Ki values of 
various cystatins have been summarized in Table 1.3. 
The increasing values of Ki with a increase in the substrate concentration 
suggests the inhibition to be competitive (Figs. 4.31, 4.32, 4.33). This finding is 
supported by the apparent results of Nicklin and Barrett (1984) for the inhibition 
of human cathepsin B by chicken cystatin. They obtained Ki(app) values of 1.85 
and 3.68nM with the substrates of 0.05 and 0.39mM, respectively. 
The ICjQ values have been summarised in Table 4.4. The isoforms I and II have 
ICjp value of 0.09|iM and 0.079|iM with papain and highest value of 0.113|iM 
and 0.125nM with bromelain. Low Ic^ ^ values suggest a greater affinity for the 
inhibitor towards the enzyme. Hence, the lowest value for papain further justifies 
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the higher affinity of the purified cystatin isoforms for papain. Katumuma and 
Kominami (1985) have found the ICj^  value of 0.16(ig of the inhibitor isolated 
from rat liver for papain and 0.46^g for ficin and Ic^ g value of 4.2|ig for 
cathepsin B and 0.14|j.g for cathepsin H. 
Tight binding inhibitors have high association rate constants. Among the three 
thiol proteinases, as expected papain has highest K ,^ (association rate constant) of 
1.5x10^ and 8.6x10'* for isoforms I and II respectively (Table 4.4). Ahhough 
bromelain exhibited lowest aflSnity but its K ,^ is higher than that obtained for ficin 
with isoform I. It is difficult to explain the discrepancy between Ki and K ,^ value 
obtained for papain and bromelain. Similarly, higher values of K ,^ have been 
obtained by Bjork and Ylinenjarvi (1989) for chicken cystatin which is 9.9x10* M" 
's"' with papain. Earlier, Nicklin and Barrett (1984) performed a K ,^ of 1x10^ M' 
' s ' and 6.3x10* M ' s ' for chicken cystatin v^th papain and dipeptidyl peptidase I 
and 4.3x10* M ' s ' with ficin. 
However, the K ,^ values lower than 1x10^ M ' s ' for papain and dipeptidyl 
peptidase I with chicken cystatin are similar to the highest rates reported for 
serine proteinase inhibitors (Means et al, 1974). 
The proteinases having low Ki have high K^^ and low K^ ^ and half life of the 
complex. This suggests the stability of the enzyme inhibitor complex (EI) and 
complex formation is very rapid (Table 4.4). The values of K j are consistent with 
K, values of chicken cystatin; 5x10's' with papain and 2.3x10'^s' with cathepsin 
B (Nicklin and Barrett, 1984). 
Hence, the data obatined gives a comprehensive information about the kinetics of 
the purified isoforms I and II with papain, ficin and bromelain showing lowest 
Ki(app) with papain and inhibition of bromelain was also observed although with 
high Ki(app) value. 
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The physiological role of free radicals have become a prominent area of interest 
in antioxidant-prooxidant research (Minghetti and Levi, 1988; Mohanakumar et al, 
1998). The major source of these radicals in biological systems are modest 
leakages from the electron transport chains of mitochondria, chloroplasts and 
endoplasmic reticulum (Dean et al., 1997). Proteins may be the critical targets of 
ROS because they are present inside and outside the cell in high concentration. 
Modification of proteins by free radicals may have an amplified effect on their 
functions like susceptibility to proteases, degradation, etc. Davies (1987) reported 
that proteins which have been exposed to certain oxygen radicals exhibit altered 
primary, secondary and tertiary structure and can undergo spontaneous 
fragmentation. 
Among the many sensitizers available, riboflavin is of special importance because 
of its widespread occurrence as coloured pigment (Britton, 1983) and as an 
integral component of flavin coenzymes (Zubay, 1989). photoillumination of 
riboflavin produces superoxide radical, singlet state oxygen and flavin radical 
(Kumari et al., 1996; Kim et al., 1993) and substantial amount of hydrogen 
peroxide (Sato et al., 1995). In view of the relevance of riboflavin in 
physiological processes and its ability to produce ROS upon photoexcitation, it is 
considered to be a suitable model to investigate the possible mechanism of photo-
oxidation of biological entities (Tsia et al., 1985) 
Treatment of purified cystatin with photoilluminated riboflavin for varying time 
period resulted in the increase in its activity for 30min and then a rapid loss in 
the inhibitory activity. The inhibitor concentration dependent experiment showed an 
increase in the activity giving similar results (Fig.4.40). This enhancement in the 
activity can be explained by the fact that oxidation leads to a conformational 
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change which increases the hydrophobicity (Cervera and Levine, 1988). As a 
result of this increase in hydrophobicity cystatin activity increases. It can also be 
suggested that ROS leads to a favourable conformational change exposing the 
reactive domains of the protein on the surface (Pacifici et al., 1993). The result 
of the loss in activity is in accordance to the reports that oxidative modification 
of proteins for longer time period can render them inactive and susceptible to 
hydrolysis by a number of proteinases (Fligiel et al., 1984; Davies, 1987; Wolff 
and Dean, 1986). The result is supported by the data obtained by fluorescence 
and PAGE. 
Higher concentrations of riboflavin induced crosslinking of the inhibitor leading to 
aggregation (Fig. 4.41A) and complete degradation was obtained after 5h 
incubation with 100|iM riboflavin (Fig. 4.41B). Similar work was done by Wolff 
et al (1986), Davies (1987), Starke-Reed and Oliver (1989), Stadtman (1992) and 
Rivett et al (1985) that the exposure of protein to oxygen radicals both in vivo 
and in vitro exposes the hydrophobic groups which may lead to subsequent 
aggregation. Free radicals such as hydroxy! radical can fi-agment and cross link 
proteins (Wolff et al., 1986; Schuesslar and Schilling, 1984). In the presence of 
oxygen crosslinking is there but fi"agmentation is much more pronounced. Hence, 
it can be said that hydroxyl radical is responsible for the aggregation (Fig. 4.41 A) 
and as the system is incubated for longer time in the presence of oxygen it also 
leads to degradation of the cystatin. Similar effect has been reported for BSA 
(Jazzar and Naseem, 1994). 
Iron and copper are biologically important transition metal ions with their reduced 
forms capable of rapidly cleaving organic compounds forming radicals that can 
initiate chain reactions (Dean et al., 1997). The results of the interaction of the 
copper (Cu) ions with cystatin and riboflavin are depicted in Table 4.5. The 
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photoilluminated system of cystatin, riboflavin and Cu(II) was completely inactive. 
However, similar system exhibited 26% activity in the dark and 50% activity in 
absence of Cu(II) in dark. This result shows that Cu (II) in itself is not 
interferring with cystatin, it is helping in the production of free radicals by 
photoilluminated riboflavin or it converts the products of ROS generating system 
to highly reactive hydroxyl radicals (Stadtman and Levine, 1992). As riboflavin 
alone has little effect on cystatin, the observed loss in the inhibitory activity of 
cystatin could be due to the combined effect of Cu(II) and photoilluminated 
riboflavin. Analysis of the ROS involved by their scavengers confirmed the 
involvement of hydroxyl radicals (Fig.4.42A). Photoactivated riboflavin in the 
presence of Cu(II), water and molecular oxygen generates hydroxyl radical (Jazzar 
and Naseem, 1996) and causes fragmentation of proteins (Pauwels et al., 1985). 
It was found that flavin triplet state and hydroxyl radicals are involved in the 
oxidation. Singlet oxygen ('O )^ was also involved to some extent (Fig.4.42B). The 
production of hydroxyl radical is inline with the observed aggregation and 
degradation of cystatin. Singlet oxygen ('O^) species have been reported to 
participate in photosensitizer induced inactivation of enzymes such as catalase 
(Gantchev and Lier, 1995). 
Fluorescence studies of the riboflavin treated cystatin exhibited rapid and major 
conformational changes in the inhibitor (Fig.4.43A,B). Complete quenching resulted 
as the absorbing groups were buried. The irreversible nature of the damage to 
the structure and unfolding of the inhibitor was justified after removing riboflavin 
(Fig.4.44). The red shifl may be because of the increase in polarity due to an 
improved access of solvent to the fluorophores. The increase in yield is due to 
loss of quenching obtained by loosening of the protein structure (Sommers and 
Kronman, 1980). Similar pattern was observed in the UV absorption spectra. The 
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reversal of the inhibitory activity after removing riboflavin and modification of 
intact structure is an interesting finding. Figure 4.45 shows UV spectra of 
riboflavin indicating the disappearance of a peak at 440nm. It is established that 
hydroxyl radical attacks riboflavin in the ground state and converts it to 
hydroxylated riboflavin leading to loss of conjugation and decrease in the 
absorption peak at 440nm. 
Keeping in view these findings, evolutionarily we can place cystatin K in between 
stefins and kininogens. According to the model for genealogy (Muller-Esterl et al., 
1985) it can be suggested that cystatin K is a direct descendent of gene block 
'A' constituting stefins which did not undergo fusion with another building block 
'B' (Fusion of A and B leads to formation of cystatin gene which fiirther by 
gene triplication leads to the formation of kininogen). Gene block A denotes the 
N-terminal of the long internal repeats of human kininogen heavy chain. Cystatin 
K N-terminal has 33.3% homology with human and bovine kininogen further 
justifies cystatin K to be a new class of cystatin. Finally, the present discussion 
thoroughly shows that the kidney cystatin exhibited properties which lie in 
between the class I, II and III of cystatin super family. The high molecular 
weight, presence of carbohydrate moieties, lack of disulphide bonds, high stability 
to temperature arid pH, anomalous cleavage pattern by the nonspecific proteinases, 
immunological identity with LMW kininogens, unique N-terminal sequence, specific 
spectral and kinetic behaviour, justifies it to be placed into a new class of 
cystatin namely, 'cystatin K'. 
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